

Multiscale integration of human and single-cell variations reveals unadjuvanted vaccine high responders are naturally adjuvanted

Matthew P. Mulè^{1,2}, Andrew J. Martins¹, Foo Cheung³, Rohit Farmer³, Brian Sellers³, Juan A. Quiel³, Arjun Jain¹, Yuri Kotliarov³, Neha Bansal¹, Jinguo Chen³, Pamela L. Schwartzberg^{4,5}, John S. Tsang^{*1,3}

1. Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA

2. NIH-Oxford-Cambridge Scholars Program; Department of Medicine, University of Cambridge, Cambridge, UK.

3. NIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA.

4. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

5. Cell Signaling and Immunity Section, NIAID, NIH, Bethesda, MD, USA

*Correspondence (JST): john.tsang@yale.edu

Abstract

Advances in multimodal single cell analysis can empower high-resolution dissection of human vaccination responses. The resulting data capture multiple layers of biological variations, including molecular and cellular states, vaccine formulations, inter- and intra-subject differences, and responses unfolding over time. Transforming such data into biological insight remains a major challenge. Here we present a systematic framework applied to multimodal single cell data obtained before and after influenza vaccination without adjuvants or pandemic H5N1 vaccination with the AS03 adjuvant. Our approach pinpoints responses shared across or unique to specific cell types and identifies adjuvant specific signatures, including pro-survival transcriptional states in B lymphocytes that emerged one day after vaccination. We also reveal that high antibody responders to the unadjuvanted vaccine have a distinct baseline involving a rewired network of cell type specific transcriptional states. Remarkably, the status of certain innate immune cells in this network in high responders of the unadjuvanted vaccine appear “naturally adjuvanted”: they resemble phenotypes induced early in the same

32 cells only by vaccination with AS03. Furthermore, these cell subsets have elevated
33 frequency in the blood at baseline and increased cell-intrinsic phospho-signaling
34 responses after LPS stimulation *ex vivo* in high compared to low responders. Our
35 findings identify how variation in the status of multiple immune cell types at baseline
36 may drive robust differences in innate and adaptive responses to vaccination and thus
37 open new avenues for vaccine development and immune response engineering in
38 humans.

40 Introduction

41
42 Human immune systems exhibit substantial person-to-person variation^{1–4}. Population
43 variations in immune response outcomes to the same perturbation, such as antibody
44 responses to vaccination, can be linked to cellular and molecular immune system
45 components using top-down systems biology approaches^{4,5}. Such studies have used
46 unbiased immune profiling to identify signatures of response to perturbations and
47 predictors of outcomes such as antibody response to vaccination^{6–14}, uncovering
48 contributions from intrinsic factors, such as genetics¹⁵, age^{16,17}, and sex¹⁸. Furthermore,
49 accumulating evidence from these studies supports the hypothesis that immune system
50 status prior to a perturbation can predict and potentially influence both response quality
51 and quantity^{6,16,19–23}. For example, we identified transcriptome signatures reflective of
52 an immune system “set point” predictive of higher antibody response following
53 vaccination in healthy individuals²²; the same signature when evaluated during relative
54 clinical quiescence was also linked to increased plasma cell related transcriptomic
55 activity during disease flares in lupus patients. More recently, blood transcriptome
56 profiling studies identified prognostic signatures in healthy children at risk of type 1
57 diabetes prior to development and onset of the disease²⁴, and at baseline in cancer
58 patients prior to immunotherapy induced autoimmunity^{25,26}.

59
60 While the biomarker signatures identified thus far are informative, technological
61 limitations hinder a high-resolution and holistic view of immune cell processes that

62 underlie baseline set points that predict and potentially determine optimal
63 responses^{27,28}. Bulk blood transcriptomic profiles are confounded by substantial inter-
64 individual variations in circulating immune cell subset frequency^{6,29,30}, while protein
65 based phenotypes measured using cytometry alone often cannot assess internal cell
66 states such as those captured by transcriptomics. Single cell transcriptomics can better
67 resolve cell states but interpretation remains challenging when measuring chromatin
68 accessibility or mRNA alone without utilizing, for example, existing knowledge
69 cataloging immune cell types and subsets using surface protein markers^{6,29–31}. Multi-
70 modal single cell transcriptome and protein profiling methods such as CITE-seq³² are
71 promising for unifying these modalities; however, the integrative analysis of timed
72 perturbation responses including the decomposition of meaningful biological variations
73 spanning different size scales from individual human subjects to cell types and single
74 cells remains a major challenge.

75
76 In this work, we developed a multilevel modeling framework to integrate human
77 population, temporal, and single cell variations. We applied this framework to extract
78 vaccine response kinetics and cell states, and attributed cell type specific transcriptomic
79 variations to age, sex, subject, perturbation, and time. Using CITE-seq³², we profiled
80 PBMCs from 26 subjects before and after vaccination with two different pandemic
81 influenza vaccines. Individuals were nested into three groups: those with 1) high or 2)
82 low antibody responses to an unadjuvanted influenza vaccine and 3) individuals
83 vaccinated with an AS03 adjuvanted vaccine against H5N1 influenza. We further
84 revealed previously unknown, cell type specific phenotypes specifically induced by
85 AS03³³. In addition, we unbiasedly defined the landscape of baseline immune
86 phenotypes linked to high antibody responses, demonstrating that these do not merely
87 reflect the phenotypes of a single cell type but instead capture an extensive correlated
88 set of phenotypes across different cell types. Furthermore, by comparing the baseline
89 (prevaccination) cell type specific predictors of unadjuvanted vaccine responses with
90 phenotypes induced specifically by the unadjuvanted influenza vaccine, the COVID-19
91 mRNA vaccine, and the AS03 adjuvanted H5N1 vaccine revealed that high responders

92 to the unadjuvanted vaccine were “naturally adjuvanted” at baseline. This concept was
93 further buttressed by data from phosphoprotein signaling responses to *ex vivo* cell
94 stimulation. Our integrative approach paves the way for multiscale analysis of timed
95 perturbation studies using multimodal single cell data in humans. Furthermore, our
96 findings suggest cell type specific targets of immune response engineering and vaccine
97 development.

98 99 **Results**

100 101 **Multimodal single cell profiling to assess human response variations to timed** 102 **vaccine perturbations**

103
104 To generate a multimodal single cell data set that captured biological variations
105 spanning molecular and cellular states, vaccine formulations, inter- and intra-subject
106 differences, and response kinetics, we assessed 52 PBMC samples from 26 donors
107 pre- and post-vaccination using CITE-seq (Figure 1a). Subjects received either the 2009
108 seasonal and pandemic type A strain vaccine combination, or an H5N1 avian influenza
109 strain formulated with oil in emulsion adjuvant AS03^{6,34}. For the AS03 group, we
110 focused on the baseline and innate response (day 1) time-points since AS03 is known
111 to elicit a strong early response^{35,36}. For the unadjuvanted seasonal influenza vaccine,
112 twenty subjects with high (n=10) and low (n=10) antibody responses were selected from
113 our cohort of 63 individuals that we previously profiled and stratified into high, mid, and
114 low responders based on antibody titer fold change adjusted for age, sex ethnicity and
115 pre-existing immunity^{6,22}. These 20 individuals were profiled at baseline and select
116 subsets of individuals on day 1 or 7 post vaccination to assess the innate and adaptive
117 cellular responses (**Figure 1a**). We analyzed sources of technical noise in CITE-seq
118 surface protein expression data by using our recently developed normalization method
119 called dsb³⁷, then assessed the robustness of CITE-seq to recover and unify known cell
120 surface and transcriptome phenotypes. For example, both activated B cells and
121 plasmablasts could be distinguished based on the expression of CITE-seq surface

122 protein markers CD19, CD71, CD20, and CD38. We further confirmed that the gated
123 cells exhibit transcriptional signatures³⁸ derived previously from these cell subsets after
124 FACS-sorting (**Figure S1a**).

125

126 **Transcriptome variation decomposition into surface protein-based cell type,** 127 **individual, age, sex, and vaccination effects**

128

129 Cells clustered using the 82 surface proteins were enriched for known immune
130 phenotypes (**Figure S1 c, d**). Cells from individual subjects at different timepoints were
131 represented in a majority of cell clusters (**Figure S1e,f**). Some cell clusters were
132 dominated by cells from two to three subjects (e.g., NKT and CD57+ CD4 T cells); this
133 likely reflects individualistic phenotypes as the samples from different timepoints from
134 the same individuals were also present in the same clusters, suggesting that these
135 phenotypes represent temporally stable, within-individual variations⁶ (**Figure S1f**).

136

137 Instead of analyzing one variable at a time, we next deconstructed the transcriptional
138 variation of each gene into that attributable to cell types, individuals, intrinsic factors
139 (age, sex), and vaccination responses (**Figure 1b**) using multivariate mixed effects
140 models. For each gene, these models quantify contributions of biological factors (such
141 as cell type or subject effects) toward observed expression variation, including adjusting
142 for dependency among repeated measures from the same individuals (see Methods).
143 Models were first fit to each transcript across 780 transcriptome (“pseudobulk”) libraries
144 indexed by cell type, individual, and timepoint (**Figure 1c, columns**). Variance patterns
145 for each gene in every cell type are provided in Supplemental Tables 3 and 4. This
146 analysis revealed that cell type explained more than 30% of the variation across the
147 transcriptome (range 0-100%; **Figure 1d, top**); this observation is consistent with the
148 fact that different cell types have distinct transcriptome profiles^{39,40}. To identify cell type
149 intrinsic and vaccination effects independent of differences among cell types, we next fit
150 models within the cell subsets defined by surface proteins (**Figure 1d, bottom**). For
151 example, this analysis revealed factors contributing to the extensive differences among

Figure 1




Figure 1. Multimodal single cell portraits of human vaccination response through within cluster mixed models comparing vaccination effects over time

a. Human vaccination response study outline; CITE-seq data was generated from n=52 PBMC matched pre- and post-vaccination PBMC samples from n=26 subjects including 2 response groups and two vaccine formulations. Numbers in the boxes indicates the number of samples run with CITE-seq. 10 high and 10 low responders from the 2009 TIV + pandemic H1N1 influenza vaccination without adjuvant were profiled with a subset of 8 and 12 subjects split evenly between high and low responders profiled on day 1 and 7 respectively. 6 subjects vaccinated with a pandemic H5N1 avian influenza vaccine formulated with adjuvant AS03 were profiled at baseline and day 1 post vaccination. **b.** The hierarchical structure of the data for a single cluster is shown to motivate necessity of multilevel modeling approach for transcriptome analysis. Clusters are based on surface protein (select proteins from naïve B cell cluster shown); within each cluster modeled with weighted mixed effects models clusters are represented by cells from PBMC samples indexed by individual, timepoint and different response groups (high and low responders) and vaccine group (unadjuvanted vs adjuvanted). **c.** For each of 780 samples aggregated by protein based cell type and individual x timepoint, the median dsb normalized protein expression in each cell type is shown—colors of cell types are the same as shown in d. **d.** Top: the fraction of variance explained in a multivariate model across libraries aggregated by cell type, individual and timepoint; bottom: as in the top panel, but here with models fit within each protein based cell type, i.e. within colored columns of c. **e.** Variance fractions for an example group of 5 genes from the multivariate mixed model fit within CD14 monocytes with additional visualizations of gene expression (y axis) vs the experimental factor (x axis) explaining maximal variance for the 5 genes. **f.** Top: enrichment of pathways in the MsidDB Hallmark gene sets based on genes ranked by their variance explained by age; subset of genes with positive association with age in CD8 naïve and CD161+ T cell clusters; bottom: select genes positively associated with age within the two cell types.

152 CD14+ classical monocytes; 5 example genes are shown in (**Figure 1e**). As expected,
153 sex almost completely explained the variation in the expression of a Y-linked gene
154 (DDX3Y). A transcription factor genetically linked to rheumatological pathology⁴¹
155 (PPARGC1B) and an apoptosis regulator (TP53RK) were negatively and positively
156 associated with age, respectively. Overall, our approach identified substantial between-
157 subject variations for many genes (**Figure 1d**, see “SubjectID”). For example, inter-
158 subject differences accounted for nearly 100% of expression variation in TMEM176B,
159 an inflammasome signaling regulator⁴², suggesting that inflammasome function could
160 have substantial individuality in the human population. Temporal variation (e.g.,
161 differences relative to baseline following vaccination) accounted for more than 50% of
162 the expression differences in STAT1; a separate differential expression model revealed
163 that vaccination induced expression of this gene within monocytes a day after
164 vaccination (see below). Age was also a major contributor, particularly in genes within
165 the CD8 naïve and CD8+ CD161+ T cells relative to other cell types; inflammatory
166 processes were specifically enriched among genes positively correlated with age
167 (**Figure 1f**), consistent with sterile inflammation linked to aging⁴³ or “inflammaging”.
168 Thus, our approach provides a global view of the extent by which different biological
169 factors contribute to gene expression variation.

170

171 **Single cell deconvolution of the early response to unadjuvanted influenza** 172 **vaccination reveals both cell type-specific and -agnostic patterns**

173

174 Given that most of the known transcriptional response signatures of vaccination were
175 derived using whole blood/PBMC profiling, we next assessed time-associated changes
176 from our mixed effects models to identify cell type specific responses elicited by
177 unadjuvanted vaccination on days 1 and 7 (after modeling between individual variation
178 and adjusting for age, sex, baseline antibody titers, and other technical factors - see
179 Methods). Gene set enrichment analysis revealed that day 7 responses comprised
180 naïve B cell and CD4+ memory T cell activation and metabolic processes; however,
181 some are not significant after FDR correction and these effects were generally weaker

182 than early response effects described below (**Figure S2a,b**). Changes in circulating
183 plasmablast frequencies were thought to drive whole blood transcriptome signatures
184 (typically measured on day 7-12 post vaccination) predictive of antibody response to
185 multiple vaccines^{6-8,44}. Indeed, here plasmablasts had the most elevated signature
186 score (i.e., average expression of genes we compiled based on previous day-7 bulk
187 transcriptome signatures predictive of antibody responses) in our day 7 vs. day 0
188 comparison relative to other cell subsets (**Figure S2c**). B cell maturation antigen
189 (BCMA) receptor (TNFRSF17) had the highest fold change in both bulk microarray and
190 “pseudobulk” CITE-seq data (**Figure S2d**). Deconvolution of the CITE-seq sequencing
191 reads to each cell type revealed that nearly all the TNFRSF17 counts (see Methods)
192 were derived from the day-7 CD38^{high} CD20⁻ plasmablast cells and not from naïve or
193 memory B cell subsets (**Figure S2e**).

194
195 Unadjuvanted influenza vaccination response studies consistently report interferon
196 stimulated gene expression (ISG) detected early (1-3 days) post vaccination in bulk
197 blood transcriptomic data. Furthermore, elevation of ISG and antigen presentation
198 genes on day 1 has been found to correlate with higher antibody response¹¹, although
199 the cellular origins of these responses were not fully resolved. Based on microarray
200 profiling of sorted cell subsets, early reports suggested that this signal originated
201 primarily from DCs on day 3⁴⁵ or monocyte/granulocytes on day 1¹³. Here, unbiased
202 CITE-seq assessment using curated gene sets, including influenza vaccine response
203 signatures obtained from the literature that were derived from bulk transcriptomic data
204 (See **Supplementary Table 1**), identified three broad patterns of responses 24 hours
205 following vaccination. The first pattern was characterized by genes downstream of type I
206 and type II interferon signaling pathways that are shared across cell types (Figure 2a).
207 46 shared, “core genes” were collectively induced in at least 5 cell types (**Figure S2f**),
208 including the transcription factors IRF1 (notably, induced across 15 cell types), STAT1,
209 IRF7, and IRF9. Also included were pattern recognition receptor (PRR) genes IFITM1
210 and IFITM3, inhibitors of viral transcription GBP1⁴⁶ and ISG15⁴⁷, and antigen
211 presentation genes TAP1, and PSMB9 (**Figure S2f**). The second pattern encompassed

212 responses unique to classical and nonclassical monocytes, such as adhesion molecule
213 ICAM1, JAK2, antigen presentation / HLA genes, and inhibitors of viral replication
214 OAS3⁴⁸, and ISG20⁴⁹. The third pattern pointed to more individual cell-type specific
215 responses (**Figure S2g**), notably, inflammatory processes induced within classical
216 monocytes. The “reactome interferon signaling” genes (**Figure 2a**) captured all three
217 response patterns, with 10-15 shared ISGs across multiple cell subsets, a specific set of
218 ISGs shared by classical and non-classical monocytes, and a set of classical monocyte
219 specific genes (**Figure 2b**). The expression of these genes in classical monocytes alone
220 clustered samples by time relative to vaccination, suggesting that they were induced in
221 a coordinated manner across individuals after vaccination (**Figure 2c**).

222
223 Genes driving the classical monocyte “IL6 production” pathway reflected early initiators
224 of inflammation MYD88, DDX-58 (RIG-I), TNF and TRAF6. Inflammatory processes
225 were further implicated by monocyte specific expression of IL-15, and chemokine
226 CCL2⁵⁰ (**Figure S2g**). Classical monocytes were also enriched for hypoxia and
227 mTORC1 signaling pathways (**Figure 2a**). While natural influenza infection can activate
228 and subvert mTOR signaling to support viral replication⁵¹, this signal following
229 inactivated vaccination was more likely to reflect the role of mTOR in inflammation⁵².
230 The genes driving this enrichment signal (“leading-edge genes”) suggested that mTOR
231 induced glycolytic metabolism might be involved: this process is known to be induced
232 after VZV vaccination⁵³ and is linked to non-specific innate memory in monocytes⁵⁴.
233 mTOR enrichment within CD25+ CD4 effector T cells, MAIT-like cells, mDCs and NK
234 cells may have been intrinsically induced by TIV or by monocyte specific expression of
235 IL-15 (**Figure S2g**), a cytokine that can activate mTOR in human NK cells⁵⁵. These cell-
236 specific and shared unadjuvanted vaccine response perturbations and driver genes are
237 provided in **Supplementary Table 2**.

238
239 We next explored how time associated response signatures from our statistical models
240 could be coupled to “bottom up” single cell computational reconstructions of
241 transcriptional dynamics induced by vaccination. By using single monocytes from both

Figure 2




Figure 2. Top down and bottom up deconstruction of transcriptome perturbations induced day 1 post vaccination with seasonal TIV + 2009 pandemic strain vaccine

a. Day 1 post vaccination transcriptional response within protein-based cell types. Gene set enrichment (orange = positive enrichment/upregulation, black= negative enrichment/downregulation) of modules based on genes ranked by pseudobulk weighted linear mixed effects model baseline vs day 1 effect size. The broad category of each curated module / pathway is labeled on the right margin; see supplemental table 1. **b.** Leading edge genes from the reactome interferon signaling module; cell types shown with enrichment at adjusted p value < 0.05. **c.** Log counts per million of aggregated data for each subject within CD14 monocytes defined by protein of leading edge genes from the "interferon signaling" module CD14 monocyte day 1 enrichment demonstrate a coordinated post vaccination across individuals (hierarchically clustered genes and samples). **d.** DDR-tree algorithm constructed with baseline and day 1 post vaccination cells. Component 1 and component 2 are latent space embeddings based on mRNA only for single monocytes as determined by the DDR-tree algorithm. Each point is a single cell and is labeled by pseudotime as calculated by monocle. The timepoint relative to vaccination of each cell along mRNA trajectory component 1 is highlighted in the top marginal histogram; cells are colored by inferred pseudotime. Three branches from left to right are enriched for resting classical monocytes, activated classical monocytes from post vaccination, and nonclassical monocytes. Cells progressively downregulate CD14 and upregulate CD16 protein level along the rightmost branch; protein data shown in the bottom margin basis spline fit to dsb normalized protein level for CD14 and CD16 (protein levels were not used to construct the trajectory). **e.** Gene expression of select leading edge genes from enrichments in CD14 monocytes based on branch-dependent differential expression show two broad patterns. Pattern 1 genes are perturbed by vaccination with highest expression in post vaccination classical monocytes – dashed line at pseudotime value of 9.5 represents the peak of activation. Pattern 2 genes continuously increase across pseudotime and have highest expression in CD16+ CD14- non-classical monocytes. The top row shows example genes from each category. The bottom row shows the subset of genes falling into each category from the combined hallmark MTORC1 signaling/Hypoxia pathways and reactome interferon signaling pathways. Below each category / pathway, enrichment of gene ontology (GO) biological process and KEGG pathways for the subset of genes from each pathway and category.

242 days 0 and 1 samples, we derived a pseudotime, tree-based latent cell-phenotype
243 space via a “reversed graph embedding” algorithm^{56,57} (**Figure. 2d**). CD14 and CD16
244 surface protein expression patterns allowed identification of cell subset enrichment at
245 the ends of the three tree branches (**Figure 2d, bottom margin**): pre-vaccination
246 classical monocytes along the left branch, their day 1 counterparts in the top branch,
247 and the non-classical monocytes from both before and after vaccination enriched in the
248 right branch. Integrating the monocyte specific vaccination response phenotypes from
249 above (Figure 2a) with this latent space visualization identified two categories of genes
250 based on branch-dependent differential expression (see Methods). Category 1 genes
251 mainly reflected vaccine perturbation effects within either CD14 monocytes alone (e.g.,
252 CCL2) or both within CD14 and CD16 monocytes (e.g., TNFSF10), whereas category 2
253 genes (e.g., IFITM2, FCERG1) captured differences and potential differentiation
254 between classical and non-classical monocytes; these genes continuously increased
255 across the spectrum of pseudotime with the highest expression in nonclassical
256 monocytes (**Figure 2e, top row**). This analysis also revealed that IFN response genes
257 in Figure 2c mostly belonged to category 1 (more than 40 genes) except for 5 genes,
258 PTPN1, IFITM2, IFITM3, HLA-C and EIF4E2 which belonged to category 2. The mTOR
259 and hypoxia pathway genes followed a similar pattern, though notably the genes falling
260 in category 2 were more enriched for glycolysis than those in category 1, which were
261 more enriched for ER stress (**Figure 2e, bottom**). These results illustrate how
262 integrating effects associated with day 1 changes following vaccination (“real time”) and
263 single-cell latent space/pseudotime reconstruction can highlight interwoven cellular
264 activation and differentiation processes and reveal finer shades of phenotypic variation
265 in response to vaccination.

266

267 **The AS03 adjuvant induces unique myeloid innate-sensing and B-cell anti-** 268 **apoptosis enhancement signatures compared to unadjuvanted vaccination**

269

270 We next examined early response (day 1) variations attributable to the vaccine adjuvant
271 AS03. AS03 is known to elicit both higher level and diversity of anti-influenza antibodies

272 compared to unadjuvanted vaccines, even when formulated with a low antigen dose³³.
273 Previous studies of transcriptional responses to AS03 adjuvanted vaccines revealed
274 strong early induction of ISGs in innate immune cells^{33,35,36,58} when comparing against a
275 low-dose antigen control formulated with PBS. Here we applied a statistical contrast
276 defining the difference in the day 1 responses (relative to baseline) between the AS03
277 adjuvanted vaccine versus the unadjuvanted vaccine described above. We then
278 validated these signatures using an independent data set from profiling FACS-sorted
279 immune cells (e.g., total B and T cells) from subjects receiving the same vaccine
280 formulated with AS03 versus PBS⁵⁸ (**Figure 3a, Figure S3a**). We first noticed positive
281 enrichment of several pathways related to surface receptors in monocytes and mDCs
282 (**Figure 3b, red**); these were highly concordant with data from similar innate cell
283 subsets in the validation cohort (**Figure 3b, light blue**). The leading-edge genes driving
284 these enrichments include immune receptors recognizing different classes of pathogens
285 (beyond just the receptors recognizing specific molecular patterns in the vaccine), thus
286 suggesting expansive upregulation of receptors to increase the capacity of cells to
287 sense environmental signals. For example, Toll Like Receptors (TLRs) recognizing both
288 bacterial and viral molecular patterns TLR1, TLR4, TLR5, and TLR8 were among the
289 leading-edge genes in the CD14 monocyte module “M16”, as was FPR2, which is
290 known to induce immune cell chemotaxis in response to bacterial metabolites⁵⁹.
291 Examination of genes with strong AS03-specific effects beyond genes in these specific
292 sensing pathways identified additional PRRs in monocytes, for example c-GAS, a
293 cytosolic DNA sensor that activates antiviral response via STING⁶⁰ (**Figure 3c**). Within
294 mDCs, day 1 enrichment of the “rhodopsin like receptors” module was driven by genes
295 related to inflammatory chemotaxis such as FPR1⁵⁹ and CCR1⁶¹ and P2RY13, an ADP
296 sensor active during inflammation⁶², which were induced to a greater degree by AS03.
297 As with CD14+ monocytes, mDCs also had evidence of AS03 specific upregulation of
298 TLR4, the PRR for bacterial lipopolysaccharide⁶³ (**Figs. 3c-d**).

299
300 While our observations thus far are consistent with the expectation that myeloid cells
301 are key players mediating the effects of AS03, we also detected a lymphocyte signature

302 suggestive of apoptosis suppression in naïve B cells in subjects vaccinated with AS03;
303 this signature included AS03-specific downregulation of genes related to apoptosis
304 **(Figure 3e)**. Further examination of genes with the largest difference in post vaccination
305 effects in naïve B cells revealed additional AS03 specific downregulation of canonical
306 pro-apoptotic genes, including BTG1 and NOXA (PMAIP1) **(Figure 3e,f)**. NOXA
307 deficiency is known to increase lymphocyte repertoire diversity^{64,65}. B cells from NOXA^{-/-}
308 mice outcompete wild type cells for entry into the germinal center following influenza
309 vaccination and infection, and they persist longer due to inefficient apoptosis⁶⁵ and thus
310 increase the diversity of anti-influenza antibodies. As we and others have shown, AS03
311 induces antibody production against influenza clades beyond those in the vaccine^{33,34}.
312 The naïve B cells in humans after vaccination with AS03 may thus phenocopy those in
313 NOXA^{-/-} mice after influenza vaccination. Naïve B cells from subjects vaccinated with
314 AS03 also appeared more activated based on increased expression of genes linked to
315 CD40 activation^{66,67} **(Figure S3c)**. The fold-change in the CD40 activation signature
316 score (day 1/day 0) was also negatively correlated with that of an apoptosis signature
317 score in naïve B cells across individuals **(Figure 3g)**. Both the apoptosis and CD40
318 activation signatures had consistent directions of change in sorted total B cells in the
319 validation cohort **(Figure S3d)**, although the apoptosis signature itself was not
320 significant. Together, these observations suggest that AS03 may function to suppress
321 apoptosis in naïve B lymphocytes early after vaccination to prolong their survival and
322 subsequent activation. This potential increase in the diversity of the naïve B cell pool
323 (presumably with varying specificity to vaccine antigens) may help increase the diversity
324 of the subsequent B cell response. We further found that the day 42 antibody avidity to
325 both the vaccine and non-vaccine influenza strains was tightly correlated across
326 individuals immunized with the AS03 adjuvant **(Figure 3h)**, supporting the hypothesis
327 that AS03 may tune the size of the initial naïve B cell pool available to be proportionally
328 expanded in the germinal center. Together these results highlight two potential
329 mechanisms by which AS03 may drive more robust antibody responses: 1) activation of
330 broad innate sensing pathways unrestricted to only those specific to the molecular
331 patterns in the vaccine; 2) suppression of apoptosis in naïve B cells to increase the

Figure 3




Figure 3. Early transcriptional responses to AS03 adjuvanted vs non-adjuvanted vaccines

a. Schematic illustrating the approach to define AS03 adjuvant specific perturbation transcriptome phenotypes within protein based cell types. Left: unadjuvanted individuals were combined and compared to individuals receiving the AS03 adjuvanted vaccine; protein based cell types are the same as those used in Fig 2 and Supplementary Fig 2 which were defined together with the adjuvanted subjects here in combined clustering. Middle: a cohort of individuals vaccinated with AS03 vs an unadjuvanted formulation from Howard *et al.* 2017. Cell types including total T cells, B cells, monocytes and DCs were defined using surface protein and sorted using FACS followed by RNAseq at baseline and day 1. Right: the model contrasts within each cell type applied to the CITE-seq discovery and FACS validation cohorts—for each cell type genes are fit with a mixed effects model and the difference in day 1 fold change between AS03 adjuvanted and unadjuvanted subjects is calculated as shown with boxplots. Genes are then ranked for enrichment based on the effect size of this contrast reflecting AS03 specificity, e.g. modules with positive normalized enrichment score have higher day 1 fold change in the AS03 vaccine group compared to the unadjuvanted vaccine. **b.** Gene set enrichment analysis of genes ranked based on the difference in transcriptional response 24-hours post vaccination vs baseline between AS03+H5N1 vs. H1N1 non adjuvanted vaccine (i.e. ranked by the contrast effect shown as in a) in classical monocytes and mDCs. Leading edge genes driving the enrichments of the selected pathways highlighted in light blue are shown to the right. Pathways with adjusted $p < 0.01$ in the validation cohort are highlighted with an asterisk. **c.** The distribution of log counts per million from aggregated CITE-seq data for each subject of select genes driving difference in perturbation response distinct to AS03 adjuvant within CD14 monocytes. Individual gene statistics from the mixed effects model contrast: FPR2 standardized z : 2.57 p value 0.010, P2RY13 standardized z : 2.56 p value 0.010, MB21D1 (CGAS) standardized z : 2.26 p value 0.022, TLR4 standardized z 1.99 p value 0.047 and **d.** As in c for in mDCs Individual gene statistics from mixed model contrast: FPR1 standardized z 2.91 p value 0.004 P2RY13 standardized z 2.8 p value 0.0051 CCR1 standardized z 2.33 p value 0.02 TLR4 standardized z 1.85 p value 0.0642. **e.** For naïve B cells, the distribution of genes from the mixed effects model showing x axis: estimated difference in baseline vs day 1 log fold changes between AS03 adjuvanted and unadjuvanted vaccination and y axis: standardized z statistics of the fold change difference contrast. Leading edge genes from M160 are highlighted in blue, with additional canonical apoptosis genes not in M160 PMAIP1 (NOXA) and BTG1 highlighted, each with strong AS03-specific downregulation (NOXA standardized z : -2.83, p value: 0.005, BTG1 standardized z : -3.05, p value: 0.002) **f.** Expression distribution of PMAIP1 (NOXA) log counts per million of aggregated CITE-seq data across donors within naïve B cells pre and post vaccination. **g.** Pearson correlation between the day 1 fold change in the CD40 activation score and the apoptosis signature in naive B cells. **h.** The correlation between antibody avidity to the heterologous strain (x -axis – H5N1 Vietnam HA) vs the vaccine strain (y -axis – Indonesia H5N1 HA) (Pearson correlation) measured by surface plasmon resonance assay on day 42 post vaccination in subjects receiving AS03 adjuvant.

332 diversity of naïve B cells entering germinal center reaction with potential positive
333 impacts on antibody response breadth. Detailed information on these AS03 specific cell
334 perturbation phenotypes are provided in **Supplementary Table 2**.

335

336

337 **Linking baseline set point signatures to early vaccination responses reveals** 338 **natural adjuvanted baseline immune states in healthy humans**

339

340 We previously described a baseline immune set point signatures predictive of antibody
341 responses to vaccination in healthy individuals and plasma cell-associated disease
342 activities in SLE patients²². However, we had only focused on a single class of
343 signatures that was discovered earlier via flow cytometry and bulk transcriptomic
344 analyses; we also did not assess how baseline immune status overlaps with
345 transcriptional and cellular responses early after vaccination. Here we used multivariate
346 models to first perform an unbiased analysis of baseline immune cell phenotypes
347 associated with antibody responses. To understand how these baseline cell phenotypes
348 associated with the high responders were related to one another, we used correlation
349 network analysis. We then further investigated how these baseline phenotypes were
350 linked to early innate responses and how they were correlated with later cellular
351 responses (see Methods). Our first analysis revealed that effector lymphocyte and
352 innate cell phenotypes comprising the baseline predictive signatures could be grouped
353 into several functional categories based on their correlation across individuals. Together
354 these defined a multicellular set point network (**Figure 4a, Figure S4a**). Interestingly,
355 the phenotypes with the highest “hub”-like properties tended to reflect innate cell
356 surface receptor pathways in CD14+ monocytes and ISG pathways in CD16+ non-
357 classical monocytes (**Figure S4b**). Full details on the cell phenotypes and genes driving
358 the high responder network phenotype are provided in **Supplementary Table 2**. Two
359 example cell phenotypes from the network are highlighted (**Figure 4b, c**). Within CD14
360 monocytes, the “FC receptors and phagocytosis” genes include those encoding Fc
361 receptors (e.g. FCGR3A, FCGR1A, FCGR2A), regulators of cytoskeletal reorganization

362 active during phagocytosis (e.g. PAK1, ARPC5, CFL1, ARF6), and second messenger
363 signaling molecules (PIP5K1A, PIK3CD, AKT1, MAPK12, ARPC2). Remarkably, this
364 monocyte signature was correlated with 27 cell phenotypes elevated in high responders
365 (adjusted $p < 0.05$) (**Figure 4b**), including both antigen presentation genes in naïve B
366 cells and interferon response genes in CD16 monocytes (**Figure. 4b, bottom**). ISG
367 expression was elevated in a variety of cell types beyond CD16 monocytes, including
368 CD161+ MAIT-like CD8+ T cells (**Figure 4c, bottom**), within which the level of IFITM1,
369 IFITM2, ISG15 and IFI6 was increased in high responders. These baseline phenotypes
370 were also correlated to the day 7 plasmablast signature score in blood (**Figure. 4d**),
371 which was predictive of antibody responses. Thus, these correlated transcriptional
372 phenotypes at baseline, both within and across cell types, are associated with the
373 extent of day 7 plasmablast and subsequent antibody increases following vaccination.

374
375 Interestingly, the phenotypes comprising the above baseline set point network and the
376 innate signatures induced early following unadjuvanted (i.e., without AS03) vaccination
377 (see **Figure 2a**) appeared similar. We thus asked whether the cell phenotypes
378 comprising the high responder set point network were induced by vaccination by
379 statistically modeling the early (day 1) post-vaccination response of the baseline set
380 point signature genes in a cell type specific manner. This analysis revealed the same
381 phenotypes driving this multicellular high responder set point (including CD14 and CD16
382 monocytes, mDCs, and MAIT cells), were induced by vaccination coherently across all
383 individuals within the same cell subsets (**Figure 4e**). This suggests that the high
384 responder baseline set point signature indeed reflected an immune state mirroring the
385 early inflammatory responses induced by vaccination. This baseline state may have
386 primed innate responses to vaccination since it was itself further induced by vaccination.
387 Further supporting this idea, the baseline signature in monocytes and mDCs was also
388 induced one day after either dose of BNT162b2 mRNA SARS-Cov2 vaccination⁶⁸, with
389 greater elevation after the second dose in classical monocytes (**Figure 4f**). Given that
390 the lipid nanoparticle carrier in the mRNA vaccine is thought to act as an adjuvant⁶⁹,
391 these results further suggest that the baseline set point signatures might have reflected

Figure 4




Figure 4. The multicellular setpoint network of high responders their day 1 post-vaccination kinetics and coupling to day 7 plasmablast activity

a. Identification of the multicellular baseline high responder setpoint network. Gene set enrichment of modules enriched pre-vaccination (baseline) in high vs. low responders within each cell type based on genes ranked using multivariate models adjusting for age, sex, and batch. The leading edge genes from these cell type specific high responder pathway enrichments were correlated across donors within and between cell types. Within cell types, the Jaccard similarity of each pairwise leading edge gene was subtracted from the Spearman correlation coefficient to correct for correlation due to two signals sharing the same genes (within a cell type) and connectivity edges were retained in the network (see methods). **b-c** Two selected highly coupled cell phenotypes in the high responder setpoint network. The edges highlighted in red are shown below as correlations of the activity of the leading edge genes from those modules across donors within the cell type indicated by the edge. Correlation values reflect Bonferroni adjusted Spearman correlation of phenotypes across the entire network. **d.** The correlation of signature expression within cell types with the day 7 fold change in the predictive signature we previously found was predictive of antibody response associated with plasmablast activity from microarray data. **e.** The post vaccination kinetics of the components of the high responder innate setpoint network. A single cell mixed effects model of module activity was used to estimate the baseline high vs low responder effect size (red) and day 1 fold change across subjects adjusting for age, sex, number of cells per donor and a random effect for donor ID. **f.** Day 1 vs 0 prime and day 22 vs 21 boost kinetics of baseline high responder states tested in an external cohort of monocytes and DCs manually gated from CITE-seq data (GSE171964) collected on individuals vaccinated with mRNA vaccine BNT162b2. The difference in the fold change between boost (d22 vs d21) and prime (d1 vs d0) p values: mDC 0.59, CD14 monocyte < 0.001 and day 1 vs baseline p<0.001 calculated by the emmeans package based on a mixed model with a donor random effect as in e.

392 a naturally “adjuvanted” state that can enhance innate immune response potential prior
393 to stimulation.

394

395 Interestingly, we noticed that the aggregated AS03 specific early response phenotypes
396 (the union of leading edge genes driving the gene set enrichments in each cell type
397 shown in Figure 3b) were decreased rather than increased after unadjuvanted
398 vaccination, further demonstrating that they were unique to the response to AS03
399 **(Figure 5a,b)**. To further test the naturally adjuvanted baseline hypothesis, we next
400 tested whether these specific DC and monocyte signatures specifically induced by the
401 AS03 adjuvant were phenocopied by the baseline of high responders. Indeed, these
402 AS03-specific innate response phenotypes were higher at the baseline of high than low
403 responders to the unadjuvanted vaccine **(Figure 5c)**. A previous study of AS03
404 identified increased frequencies of activated HLA-DR+ monocytes 24h following
405 vaccination⁹. Again, here the high responders to unadjuvanted vaccination already had
406 elevated frequencies of HLA-DR+ monocytes⁶ at baseline **(Figure 5d)**. Furthermore, by
407 day 1 post vaccination, the frequency of these activated HLA-DR+ monocyte increased
408 with a larger effect in the high responders (effect size 3.17, $p = 0.0005$) than the low
409 responders (1.89, $p = 0.14$) **(Figure 5e)**. Thus, multiple lines of evidence, including
410 those from transcriptional and innate immune cell frequency analysis, support the
411 conclusion that the baseline immune statuses of high responders correspond to a
412 naturally adjuvanted innate immune state that mirrors not only the early responses
413 induced by the unadjuvanted vaccine, but also those specifically elicited by the AS03
414 adjuvant.

415

416 The naturally adjuvanted baseline statuses may partly reflect cell-intrinsic differences in
417 response capacity to innate immune cell stimulation. To evaluate this hypothesis, we
418 stimulated PBMCs from the same 10 high and 10 low responders (to the unadjuvanted
419 influenza vaccine) with interferon alpha, PMA plus ionomycin, and LPS, and used early
420 phosphorylation signaling responses within 15 minutes after stimulation to assess
421 whether certain cell subsets were intrinsically more responsive in transducing these

Figure 5




Figure 5 High responders have a naturally adjuvanted immune setpoint with monocytes more poised to enter blood and respond to PRR stimulation

a. Average expression of a combined gene signature reflecting the AS03 specific induced states within DCs and CD14 monocytes. **b.** Gene set enrichment of the combined AS03 specific signature on the validation cohort in analogous subsets; select adjuvant specific genes in the leading edge of the validation are shown. **c.** The average expression in high vs low responders of the mDC and CD14 monocyte AS03 specific day 1 induced validated signature tested in analogous subsets. **d.** Log cell frequency of HLA-DR+ classical monocytes as a percentage of total classical monocytes in high vs low responders at baseline, p value from a Wilcoxon rank test. **e.** The kinetics over two baseline timepoints and three post vaccination timepoints for HLA-DR+ classical monocytes. Mixed effects model with an interaction for time and response group and a random effect for subject ID—high responder effect size 3.17 p value = 0.0005, low responder effect size 1.89, p value = 0.14, difference in estimated marginal day 1 vs baseline fold change not significant, response time vs time only interaction model ANOVA p = 0.063. **f.** Schematic outlining CyTOF stimulation experiment. PBMCs isolated from high and low responders were stimulated with PRR ligands. Stimulation phenotype and markers driving stimulation were defined with HDStIM. **g.** UMAP plot of a random subset of 5000 monocytes pre and post stimulation with stimulated cells in orange and unstimulated cells in blue. **h.** Variable importance for individual phospho-protein markers determined by the Boruta algorithm which are used for automatic determination of responding cells in HDStIM. **i.** The post stimulation median marker intensity of phosphor markers within the CD14 monocyte cluster, the post stimulation aggregated data are shown due to variable baseline phospho-marker detection and effects were tested using a mixed model adjusting for batch and modeling individual variation with a random effect for donor ID. The difference in pre vs post stimulation fold changes in high vs low responders contrast estimate and p values: p38 contrast effect: 0.104, p = 0.058, pCREB contrast effect: 0.223, p = 0.024, pERK contrast effect: 0.58, p = 0.055.

external stimulatory signals (**Figure 5f**). We used CyTOF profiling for both cell surface protein and intracellular phosphorylation-based signaling readouts, and defined the responding cell populations and associated response markers by using a computational algorithm we recently developed called HDStIM⁷⁰ (**Figure 5g-h**). As expected, CD14 monocytes responded strongly to LPS as evident by increased levels of phosphorylated p38, CREB, IκBa, and ERK (**Figure 5h**). Supporting the idea that the naturally adjuvanted set point reflected cell intrinsic signaling response capacity, the difference in the post-stimulation fold-change of p38, pERK, and pCREB (after adjusting for batch and individual variation) was elevated to a greater extent in high compared to low responders (**Figure 5i**). This cell intrinsic, TLR-dependent increase in the signaling capacity of monocytes suggest that the high responders possess a baseline set point poised to mount a stronger response to stimulatory signals from the vaccine. Specifically, if this intrinsic signaling response difference extends to pattern-recognition receptors that might recognize influenza vaccine components, such as TLR3, TLR7, or TLR9, these may signal through transcription factors including IRF3 or IRF7 to activate interferon response genes, such as those encoding for ISG15 and IFN-β; these could further induce antiviral gene expression programs in both monocytes and DCs via autocrine / paracrine circuits^{71,72}. Furthermore, enhanced p38 signaling could also play a role in RIG-I induced interferon response to the vaccine^{73,74}. Together these observations provide additional insights into the mechanistic underpinnings of a naturally adjuvanted human immune set point found in healthy individuals primed to respond with more robust innate and adaptive responses following vaccination.

Discussion

In this work we introduce a framework for integrating natural human population variation with multimodal single cell variation capturing cellular states before and after a perturbation. While prevailing analysis approaches for single cell data often rely on qualitative visualization⁷⁵ and univariate analysis, these approaches are often insufficient for complex experiment designs with many samples⁷⁶ and do not provide a

452 quantitative means to integrate human and single cell variations to extract biological
453 insights. Our approach provides robust statistical methods for these complex
454 experimental designs; its application to the multimodal single cell data in this work
455 illustrated how new insights can be obtained, e.g., regarding adjuvant specific response
456 phenotypes involving naïve B cells as well as the cellular and transcriptional signatures
457 of a naturally-adjuvanted baseline immune set point. These findings advance the
458 concept that modulating baseline set points may improve immune response outcomes
459 in diverse contexts²¹. For example, the baseline immune states of the low responders
460 could be tuned to phenocopy the naturally adjuvanted innate immune state to enhance
461 their future vaccination responses; these low responders include patients who require
462 continued immunosuppression e.g. after transplantation, but need urgent vaccination in
463 a pandemic setting.

464
465 A host of approaches can be used to tune immune set points including vaccination
466 itself. For example, BCG vaccination has been known to confer nonspecific protection
467 (i.e., not just against TB) and reduce all-cause mortality in infants⁷⁷; it has also been
468 shown to potentiate nonspecific secondary innate immune cell responses in mice⁷⁸.
469 Recent phase III human trials evaluating BCG vaccination as a nonspecific
470 immunomodulator showed promise in demonstrating protection against respiratory
471 infections in the elderly⁷⁹, who tend to be immunosuppressed⁴³. It remains to be seen
472 whether the naturally adjuvanted phenotype we describe here is similar to the innate
473 immune training conferred by BCG vaccination^{80,81}, which can induce short-term innate
474 immune memory attributed to chromatin remodeling⁸². Indeed, the molecular
475 underpinnings of the naturally adjuvanted baseline transcriptional phenotype remain to
476 be determined. Preliminarily by using a computational approach⁸³ to look for
477 transcriptional factor motif enrichments, we detected significant enrichment of SPI1/
478 PU.1, IRF family members, and CEBPB, which were ranked near the top among other
479 transcription factors (TFs) predicted to regulate the above set point signature genes in
480 classical monocytes (these were ranked between 2 and 32 among 1632 tested, data not
481 shown). Intriguingly, these were some of the same TFs whose binding motifs tended to

482 have altered chromatin accessibility after LPS “training” in mouse monocytes, leading to
483 enhanced myelopoiesis and elevated extravasation of monocytes into the blood⁸⁴.

484 Future work could evaluate vaccination regimens which might optimize the longitudinal
485 persistence of this naturally adjuvanted set point.

486
487 Evaluation of larger cohorts using similar multimodal single cell approaches will help
488 assess the generalizability of our naturally occurring baseline set points. While lacking
489 the resolution of the multimodal single cell analysis framework introduced here, our
490 earlier work analyzing bulk blood transcriptome data from multiple influenza vaccine
491 studies provide independent support, including the observation of substantial inter-
492 subject variation in baseline immune states^{1,2,6,85} and an “inflammatory signaling”
493 module predictive of antibody response to influenza vaccination in multiple cohorts of
494 subjects under the age of 65¹⁶. More recent work using bulk blood transcriptomic data
495 assessing different types of vaccines revealed that individuals with a high “inflammation”
496 phenotype tended to have better antibody responses²³. What is less clear is how age
497 related inflammation is similar to or distinct from such baseline inflammatory states.
498 Earlier work suggests that tonic levels of interferon in the young are distinct from age
499 related inflammation, which may be more related to TNF signaling and its downstream
500 effects^{86,87}. Our work provides a basis for future studies to identify the extent by which
501 these bulk signatures can be resolved further by using the kind of approaches
502 introduced here.

503
504 Our study has several limitations. Profiling blood alone misses cells and processes in
505 tissues. Assessing tissues such as lymph nodes would give a more comprehensive
506 picture of vaccination response variations across individuals. Despite logistical
507 challenges of human tissue profiling, recent pioneering work using fine needle aspirates
508 or biopsies from lymph nodes^{88–90} following influenza vaccination⁹¹ have helped link
509 blood and tissue phenotypes. For example, our single cell deconvolution revealed that
510 the predictive day-7 bulk expression signatures were derived nearly exclusively from a
511 small number of plasmablast cells (Figs S2c-e). Circulating plasmablasts have been

512 shown to shared B-cell receptor sequences with those obtained from lymph node
513 biopsies⁹¹, thus the whole blood based plasmablast transcriptional signatures that have
514 been widely detected post vaccination in previous studies are, as expected and
515 supported by our results, originated from B cells in lymph nodes with shared clonality.
516 Determining the origin of the innate immune cells and their states in circulation,
517 including both DCs and monocytes, on day 1 and their connection to the cells
518 “encoding” the naturally adjuvanted baseline states remains an open problem. Given
519 that monocytes have relatively short half-life, the dynamics and status of the myeloid
520 progenitors need to be considered and may hold a key to linking immune cell status in
521 the bone marrow and shorter-lived circulating cells in blood. Tracking the clonal origins
522 of innate immune cells lacking clonal receptors in humans presents a major challenge,
523 however, recent developments in mitochondrial DNA mutation profiling using single cell
524 ATAC-seq data could be informative in this context⁹². Another open issue is the origin of
525 the naturally adjuvanted baseline immune state within individuals – what sets the set
526 point? Our recent work suggest that prior infections could modulate and establish new
527 baseline set points in humans, e.g., months after clinical recovery from mild COVID-19
528 both men and women had a temporally stable altered baseline immune state compared
529 to matching controls, and men tended to mount more robust innate and adaptive
530 responses to the seasonal influenza vaccine⁹³. As future work we can assess whether
531 and how the monocyte and DC naturally adjuvanted phenotypes overlap with those
532 stably modified by prior infections in the same cells. Finally, vaccination itself, such as
533 BCG discussed above as well as recent evidence from influenza vaccination with
534 adjuvants⁹⁴, can also potentially modulate baseline immune states. Together, our
535 framework paves the way for further studies to integrate human and single cell
536 variations over space and time in response to perturbations across biological
537 disciplines; our findings help advance a more quantitative, predictive understanding of
538 the human immune system.

541 **Methods**

542

543 **Human vaccination comparison cohorts and antibody response assessment**

544 Healthy volunteers were enrolled on the National Institutes of Health (NIH) protocols 09-
545 H-0239 (Clinicaltrials.gov: NCT01191853) and 12-H-0103 (www.clinicaltrials.gov:
546 NCT01578317). Subjects enrolled in 09-H-0239 received the 2009 seasonal influenza
547 vaccine (Novartis), and the 2009 H1N1 pandemic (Sanofi-Aventis) vaccines, both
548 without an adjuvant. Subjects in 12-H-0103 received a vaccine formulated with the
549 adjuvant AS03 containing avian influenza strain H5N1 A/Indonesia/05/2005 (GSK). In
550 both cohorts, virus neutralizing antibody titers assessed using a microneutralization
551 assay were determined as previously reported. The highest titer that suppressed virus
552 replication was determined for each strain in the 2009 inactivated influenza vaccine:
553 A/California/07/2009 [H1N1pdm09], H1N1 A/Brisbane/59/07, H3N2 A/Uruguay/716/07,
554 and B/Brisbane/60/2001 or for AS03 adjuvanted influenza vaccine, H5N1 A/Indonesia,
555 clade 2.1. High and low antibody responders to the unadjuvanted vaccination were
556 defined using the adjusted maximum fold change (AdjMFC) which adjusts the fold
557 change for the baseline antibody titer (methodological details in the supplementary
558 methods of our previous report⁶). In the unadjuvanted cohort, n=10 high responders and
559 n=10 low responders were selected for CITE-seq profiling. All subjects were analyzed
560 pre-vaccination, with a subset of 8 and 12 donors profiled on days 1 and 7 post-
561 vaccination also split evenly between high and low responders. In the adjuvant cohort,
562 n=6 subjects with robust titer responses were selected for CITE-seq.

563

564 **CITE-seq profiling of peripheral blood mononuclear cells**

565 We optimized a custom CITE-seq antibody panel of 87 markers using titration
566 experiments and stained cells with a concentration of antibody appeared to saturate
567 ligand of the cell population with the highest marker expression, or used the
568 manufacturers recommended concentration when below saturation. We stained the 52
569 PBMC samples across three experimental batches using a single pool of which were
570 combined in the optimal concentration and concentrated in an Amicon Ultra 0.5mL
571 centrifugal filter by spinning at 14,000 x g for 5 minutes. Three aliquots of 12 μ L from the

572 36 μ L volume of optimized antibody mixture was used on 3 subsequent days to minimize
573 between experiment technical variability. Frozen PBMC vials from each donor were
574 washed in pre-warmed RPMI with 10% FBS followed by PBS. 1x10⁶ cells from each
575 sample were stained with a hashing antibody⁹⁵ simultaneously with 1 μ L FC receptor
576 blocking reagent for 10 minutes on ice. After washing the hashing reaction 3 times in
577 cold PBS, cells were counted and pooled in equal ratios into a single tube and mixed.
578 The sample pool was concentrated to 5x10⁶ cells in 88 μ L of staining buffer. 12 μ L of the
579 concentrated optimized 87 antibody panel was added to stain cells (total reaction
580 volume 100 μ L) for 30 mins on ice. After washing cells, we diluted cells to 1400 cells /
581 μ L, recounted 4 aliquots of cells and 30 μ L of the stained barcoded cell pool containing
582 cells from all donors was partitioned across 6 lanes of the 10X Genomics Chromium
583 Controller for each of the 3 batches for 18 total lanes. We proceeded with library prep
584 for the 10X Genomics Chromium V2 chemistry according to the manufacturer's
585 specifications with additional steps to recover ADT and HTO libraries during SPRI bead
586 purification as outlined in the publicly available CITE-seq protocol (<https://cite-seq.com>)
587 version 2018-02-12. We clustered Illumina HiSeq 2500 flow cells with V4 reagents with
588 pooled RNA, ADT and HTO libraries in a 40:9:1 ratio (20 μ L RNA, 4.5 μ L ADT, 0.5 μ L
589 HTO). Libraries were sequenced using the Illumina HiSeq 2500 with v4 reagents. CITE-
590 seq antibody information is provided in Supplemental Table 5.

591

592 **CITE-seq data sequence alignment and sample demultiplexing**

593 Bcl2fastq version 2.20 (Illumina) was used to demultiplex sequencing data. Cell Ranger
594 version 3.0.1 (10x Genomics) was used for alignment (using the Hg19 annotation file
595 provided by 10x Genomics) and counting UMIs. The fraction of reads mapped to the
596 genome was above 90% for all lanes and sequencing saturation was typically around
597 90%. ADT and HTO alignment and UMI counting was done using CITE-seq-Count
598 version 1.4.2. We retained the "raw" output file from Cell Ranger containing all possible
599 10X cell barcodes for each 10X lane, and merged the CITE-seq-count output. For each
600 10X lane, barcodes were concatenated with a string denoting the lane of origin and data
601 for ADT, HTO and mRNA. We then utilized combined sample demultiplexing to assign

602 the donor ID and timepoint to each single cell. Both the timepoint and response class
603 were identifiable based on the hashing antibody. The first round of demultiplexing was
604 carried out via cell hashing antibodies. The union of singlets defined by the multiseq
605 deMUTiplex procedure⁹⁶ and Seurat's HTODemux function were retained for further
606 QC. Negative drops identified by HTODemux were retained for further QC and use in
607 denoising and normalizing protein data. The second round of sample demultiplexing
608 was carried out via Demuxlet⁹⁷ to assign the unique donor ID by cross-referencing
609 unique SNPs detected in mRNA single cell data against a vcf file with non-imputed
610 illumina chip based genotype data from the same donors. Demuxlet provided an
611 additional round of doublet removal via an orthogonal assay (mRNA) to antibody
612 barcode (HTO) based demultiplexing thus providing further data QC. Only cells that met
613 the following conditions were retained for further downstream QC, normalization and
614 analysis: 1) The cell must be defined as a "singlet" by antibody barcode based
615 demultiplexing and by demuxlet. 2) The identified donor from demuxlet must match one
616 of the expected donors based on cell hashing. Cells were then further QCd based on
617 mRNA using calculateQCmetrics function in scater⁹⁸. Cells were removed that had with
618 greater or less than 3.5 median absolute deviations from the median log mRNA library
619 size.

620

621 **Surface protein and mRNA count data normalization**

622 We denoised and normalized ADT data using an open source R package we developed
623 for this work called dsb³⁷ which removes noise derived from ambient unbound
624 antibodies and cell to cell technical noise. We used function DSBNormalizeProtein with
625 default parameters. We normalized mRNA on the entire dataset with the normalizeSCE
626 and multiBatchNorm functions from scran⁹⁹ using library size-based size factors.

627 Various analysis utilized aggregated mRNA data which were separately normalized
628 for analysis at the subset level as a "pseudobulk" library; single cell mRNA data were
629 also renormalized or rescaled for specific analysis as outlined below.

630

631 **Surface protein-based clustering and cell type annotation**

632 Using protein to define cell type facilitated improved interpretation of transcriptome
633 differences between vaccination groups. Cell types were defined with statistically
634 independent information, protein, from transcriptome data being modeled within each
635 cell type (Figure. 1a). We clustered cells directly on a distance matrix using the
636 parallelDist package calculated from the non-isotype-control proteins all cells using
637 Seurat's FindClusters function using parameters: $res = 1.2$, $modularity.fxn = 1$, $algorithm$
638 $= 3$ (SLM¹⁰⁰). We annotated cell types in the resulting clusters post hoc, based
639 canonical protein expression in immune cell populations. This procedure improved
640 separation of known immune populations compared to compressing protein data using
641 principal components as commonly done for higher dimensional mRNA data (data not
642 shown). Analysis of unadjuvanted vaccination responses was first done blind to the
643 adjuvanted cohort data. We thus first applied high dimensional clustering of the
644 unadjuvanted cohort and annotated cell types with additional manual gates to purify
645 canonical cell populations such as memory and naïve T cells. We next merged
646 unadjuvanted and adjuvanted cohort cells and used annotations to guide combined
647 clustering annotation, again manually refining cell populations using biaxial gating
648 scripts in R to purify cell some cell populations. For annotation, the distribution of
649 marker expression within and between clusters was compared using density histogram
650 distributions of marker expression across clusters at the single cell level, biaxial marker
651 distribution and median and mean aggregated protein expression across clusters.

652

653 **Hierarchical transcriptome variance deconstruction to infer individual (subject** 654 **intrinsic), cell type, and vaccine effects**

655 To estimate the contribution of subject intrinsic and contributors to the observed
656 variation in expression of each gene within specific cell clusters/subsets, we used the
657 variancePartition package¹⁰¹. The set of models used for estimating variance fractions
658 are distinct from but related to those used for testing differential expression and contrast
659 vaccination effects within cell subsets (see below). We first aggregated data across
660 individual, timepoint and cell type. The normalized aggregated expression was used to
661 first model the mean variance relationship using observation level weights using

662 voom¹⁰². Mixed effects linear models of the expression of each gene across the
 663 aggregated libraries were then fitted using lme4¹⁰³ with variancePartition. For each gene
 664 “y” the total variance was defined by 780 measurements derived from the 52 PBMC
 665 samples deconvolved into the 15 major protein-based cell clusters/types tested. The
 666 model fit to each gene “g” was:

$$668 \quad g = \sum_j X_j \beta_j + \sum_k Z_k a_k + \varepsilon_g$$

669
 670 Where X and Z are the matrices of fixed and varying / random effects respectively, with
 671 random effects modeled with a Gaussian distribution and errors incorporating weights
 672 calculated with voom.

$$675 \quad a_k \sim N(0, \sigma_{\alpha}^2)$$

$$677 \quad \varepsilon_g \sim N(0, \text{diag}(w_g) \sigma_{\varepsilon}^2)$$

678
 679 The variancePartition package then incorporates both fixed and random effects in
 680 calculating the fraction of variation attributable to each variable in the model. For
 681 example, the variance in g attributable to “subjectID” (i.e., differences between
 682 individuals) was modeled as a random effect is:

$$684 \quad \sigma_{gSubjectID}^2 = \frac{\sigma_{\beta SubjectID}^2}{\sum_j \sigma_{\beta_j}^2 + \sum_k \sigma_{\alpha_k}^2 + \sigma_{\varepsilon}^2}$$

685
 686 The denominator in the fraction above is the total variance of gene g, with both fixed
 687 and random effects contributing to total variance. In the first model above, age, sex,
 688 subjectID, timepoint, response /vaccine group (unadjuvanted group high vs low

689 responders, or AS03 group) cell type, and a cell type and timepoint interaction term as
690 categorical random effect variables as required by the variancePartition framework. As
691 expected, a second set of models fit within each cell type/cluster (i.e., without having
692 cell type as a variable in the model) increased the apparent variance explained by the
693 other factors given that major cell type specific expression was a key factor driving gene
694 expression variation. This model included age, sex, subjectID, timepoint, and response /
695 vaccine group (as above) and an interaction term for time and group.

696

697 **Within cell type linear mixed effect models of vaccination effects on gene** 698 **expression**

699 We used linear mixed models to test coherent effects of vaccination across individuals
700 while adjusting for subject intrinsic factors including age and gender and estimating
701 individual subject level variation. Gene expression counts were aggregated within each
702 surface protein-based cell type by summing counts within each sample. The lowest
703 frequency cell types without representation across some individuals and time relative to
704 vaccination (e.g., HSCs, donor-specific cell types, or plasmablasts which were mainly
705 detected on day 7) were excluded from this specific analysis. Three main analysis were
706 carried out to model gene expression within each cell type to estimate the following
707 vaccination effects over time across individuals: model 1) unadjuvanted subjects day 1
708 vs baseline, model 2) unadjuvanted subjects day 7 vs baseline, model 3) A contrast of
709 the difference in day 1 fold change between unadjuvanted and adjuvanted subjects in a
710 combined model – the goal of this model is to assess adjuvant specific response
711 effects. All models were fit with the 'dream' method⁹⁶ which incorporates precision
712 weights⁹⁷ in a mixed effects linear model fit using using lme4⁹⁸. For models 1 and 2
713 above (unadjuvanted vaccination effects) we fit the following model: $gene \sim 0 + time +$
714 $age + sex + (1|subjectID)$.

715

716 The fitted value for expression y of each gene g corresponds to:

717

$$y_g = \beta_{0g} + \sum_j X_j \beta_j + \varepsilon_g$$

With variables time, age, and sex represented by covariate matrix X . The β_0 term corresponds to the varying intercept for each donor represented by the (1|subjectID) term. This model thus estimates the baseline expression variation across subjects S_0 around the average γ_0 using a Gaussian distribution with standard deviation τ_g^2 to shrink estimated vaccination effects toward the population mean and adjust for non-independence of repeated measures from the same individuals, as follows:

$$\beta_{0g} = \gamma_0 + S_0$$

$$S_0 \sim N(0, \tau_g^2)$$

Errors ε_g incorporate observational weights w_g calculated using the function *voomWithDreamWeights* in a procedure similar to that described by Law *et al*¹⁰² but using the mixed model fit:

$$\varepsilon_g \sim N(0, \text{diag}(w_g) \sigma_\varepsilon^2)$$

In this model, the day 1 or day 7 effect across subjects was the time effect from the model. The mixed model standardized z statistic was then used to rank genes for gene set enrichment testing for each cell type. Model 3 was specified as *gene* ~ 0 + *group* + *age* + *sex* + (1|*subjectID*). The “group” variable corresponds to a combined factor representing the vaccine formulation received (adjuvanted vs unadjuvanted) and timepoint (baseline or day 1 post vaccination) with 4 level: “d0_AS03”, “d1_AS03”, “d0_unadjuvanted”, “d1_unadjuvanted”. A contrast matrix L_{delta} corresponding to the difference in fold changes between adjuvanted and unadjuvanted subjects was applied to test the null hypothesis of 0 difference in fold changes between the groups.

$$L_{delta} = [-1 \ 1 \ 1 \quad -1 \ 0 \ 0]$$

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

With the first four columns representing the group factor and the two 0s representing age and sex effects. The contrast fit outputs the difference in fold change after adjusting estimates for age, sex and subject variation with positive effects representing increased fold change in the adjuvant group compared to the unadjuvanted group. This contrast approach was designed to also capture genes with opposite vaccination effects in the two groups, for example, upregulation in the AS03 group and downregulation in the nonadjuvanted subjects.

Transcriptome data was uniformly processed for all fitted models above. Aggregated (summed) single cell UMI counts were normalized within each protein based cell type using the trimmed means of M values method with only genes retained with a pooled count per million above 3 using the edgeR *filterByExprs* function¹⁰⁴. Cell type specific gene filtering removed genes non expressed by each lineage from analysis ensured the model assumptions used to derive precision weights and account for the mean variance trend were met. We verified the log count per million vs. fitted residual square root standard deviation had a monotonically decreasing trend within each cell type. For the AS03 validation cohort, pre normalized data were downloaded from the study supplemental data⁵⁸ and a similar model to model 3, contrasting the difference in fold change was fit with a contrast again using a donor random intercept.

Gene set enrichment testing of vaccination effects within cell types using specific hypothesis-driven gene sets or unbiased analysis

To test enrichment of pathways based on the estimated gene coefficients corresponding to the three vaccination effects defined above, we performed gene set enrichment analysis using the fgsea¹⁰⁵ package multilevel split Monte Carlo method (version 1.16.0). Genes for each coefficient (i.e. models 1-3) and each cell type were ranked by their effect size, (the dream package empirical Bayes moderated signed z statistic), corresponding to pre vs post vaccination or the difference in fold change for model 3 (comparing unadjuvanted vs. AS03). For enrichment of the day 1 response, five gene

776 sets were derived from bulk transcriptomic data of influenza vaccination (see
777 Supplementary Table 1), and an additional 25 pathways/gene sets curated from public
778 databases were tested. For Day 7 responses and the difference in fold change between
779 adjuvanted and unadjuvanted subjects, an unbiased set of pathways were tested from
780 the Li et al. Blood Transcriptional Modules (BTM)¹⁰⁶, MSigDB Hallmark, reactome and
781 kegg databases. Over-representation of GO terms for the monocyte pseudotime gene
782 categories was assessed using enrichr¹⁰⁷.

783

784 **Inference of the baseline immune set point network**

785 To define cell type specific transcriptional phenotypes robustly associated with high vs
786 low responders of the unadjuvanted vaccine at baseline, we used limma¹⁰⁸ to fit linear
787 models of gene expression as a function of antibody response class (high vs low, coded
788 as a two-level factor) adjusting for age sex and batch (e.g. in R symbolic notation, gene
789 ~ AdjMFC + age + sex + batch) as fixed effects on aggregated (summed) data for each
790 cell type, similar to models above without varying effects for individuals:

791

$$792 \quad y_g = \sum_j X_j \beta_j + \varepsilon_g$$

793

794 Errors incorporated voom weights as above. Gene coefficients for each cell type
795 corresponding to model adjusted empirical Bayes regularized estimates for high vs low
796 responder effect at baseline were input into gene set enrichment analysis against the
797 unbiased set of pathways described above. We then calculated the average module z
798 score²² using log counts per million from each cell type of the high responder associated
799 cell phenotypes (using only high responder associated leading edge genes from gene
800 set enrichment analysis), resulting in a matrix of baseline normalized expression of
801 pathways across 20 individuals (10 high and low responders) for each cell type. We
802 next tested for correlation of these signals, both within and between cell types, by
803 calculating the spearman correlation and adjusted p values with the FDR method. We

804 noticed that within the same cell type, pathway enrichments could sometimes be driven
805 by a shared set of genes among gene sets with different pathway labels but essentially
806 shared a substantial fraction of genes. We therefore calculated the Jaccard similarity
807 coefficient of each pairwise enrichment signal (leading edge genes driving the high vs
808 low responder difference) within each cell type, and use that to adjust the correlation
809 effect sizes computed above such that the resulting quantity reflected “shared latent
810 information” (SLI) by subtracting the Jaccard similarity index from the Spearman
811 correlation coefficient ρ :

812

$$813 \quad SLI = \rho - \frac{A \cap B}{A \cup B}$$

814

815 For example, given enriched pathways A and B within a cell type, if at one extreme,
816 these two pathways are driven by the same exact shared 10 leading edge genes, the
817 Spearman ρ of their normalized expression would be equal to 1, yet this apparent
818 correlation is arbitrary since the two pathways reflect the same genes. However, the
819 shared latent information would be equal to 0 because the Jaccard similarity of the two
820 sets is also equal to 1 since the leading edge genes from the enrichments are also the
821 same. The remaining correlation strength better reflects the phenotypic coupling of
822 intracellular states across individuals after removing the signal due to leading-edge
823 gene sharing between gene sets. For inter-cellular correlations between two distinct cell
824 types, we do not subtract the Jaccard similarity of gene content from ρ as we consider
825 the same genes to be distinct signals when measured in different cell types. We further
826 constructed a sub network from a subset of cell types forming the high responder
827 baseline set point network. To identify the most highly connected processes,
828 correlations with adjusted p values < 0.05 were retained and a weighted undirected
829 network was constructed using igraph, retaining only the strongest links above the
830 median weight with weights reflecting Spearman’s Rho for intercellular connections and
831 the SLI metric described above for intracellular connections. Each node (high responder
832 cell phenotype) was also correlated across individuals with the day 7 fold change of a

833 gene expression signature⁵ reflective of plasmablast activity derived from bulk
834 microarray data from the same subjects and select high degree nodes were highlighted
835 in the text.

836

837 **Single-cell mixed-effect models of gene expression**

838 In addition to the pseudo-bulk models fitted above, we also used single cell mixed effects
839 models to assess consistency and to specifically test the early response kinetics of the
840 baseline states enriched above, including select AS03 associated response signatures
841 within innate immune cell subsets.

842

843 *Early kinetics of baseline set point phenotypes.* Each cell type specific transcriptional
844 phenotype enriched in high vs low responders in the aggregated/pseudo-bulk linear
845 model described above were scored in single cells from subjects on day 0 and day 1 as
846 the average expression of the specific leading edge genes enriched in high vs low
847 responders. The per single cell module scores were fitted with a linear mixed model for
848 each cell type to 1) re-test the baseline association (high vs. low responders) at the single
849 cell level, and 2) to test their post vaccination effect size within the same cell subset.
850 These models estimated the variance at the single-cell level instead of at the individual
851 donor cell-aggregated level. Otherwise these represent conceptually similar models as
852 the ones described above fitted using lme4 with a donor random intercept, but without
853 voom weights. Two models were tested with highly concordant resulting effect sizes: 1)
854 a parsimonious model of time relative to vaccination with a subject random effect, and 2)
855 a more complex model including the time relative to vaccination, the number of cells per
856 individual sample for a given cell type, age, sex, and a subject random effect. Normalized
857 expression of each module was standardized within each surface protein-based cell
858 cluster/subset by subtracting the mean and dividing by the standard deviation of the
859 module score across single cells within the cell type. After fitting models, the baseline
860 high vs low responder effect and the day 1 vs baseline effect sizes and standard errors
861 across subsets was calculated using the emmeans¹⁰⁹ package with a custom contrast
862 (e.g., see Figure. 4e). All models were checked for convergence criteria.

863
864 *AS03 specific regulation.* Naïve B cells were tested for expression of modules
865 hypothesized to be involved in B cell survival (see below; partly based on the literature or
866 derived from existing independent data sets). These modules were tested here for their
867 effects at the single cell level; they were then independently assessed in sorted total B
868 cells in the validation cohort⁵⁸. Two modules were defined to reflect survival of human
869 naïve B cells: 1) A CD40 activation signature²² which was derived from studies of in vitro
870 CD40 activated human B cells; 2) An apoptosis signature derived by combining signals
871 from the CITE-seq naïve B cell day 1 gene set enrichment comparing AS03 adjuvanted
872 to unadjuvanted individuals. The signals combined the specific naïve B cell leading edge
873 genes from the negatively enriched (reflecting AS03 specific downregulation) apoptosis
874 modules (with unadjusted p values < 0.1—we opted for a loser cutoff to increase
875 sensitivity): reactome activation of BH3 only proteins, KEGG p35 signaling pathway, and
876 LI.M160 leukocyte differentiation. The cell type specific leading edge genes were scored
877 as above and fitted with age and sex covariates, a combined factor for vaccine group,
878 timepoint, and random effect for subject ID, with the difference in fold changes calculated
879 using the emmeans package.

880 881 **Software for implementing analysis workflow**

882 The analysis framework described above is available in an R software package
883 “scglmmr” (<https://github.com/MattPM/scglmmr>) for analysis of single cell perturbation
884 experiment data with repeated measures and multi-individual nested group designs.
885 The software provides workflows for fitting single cell mixed models, deriving cell
886 signatures, visualization, and also includes wrapper functions to implement the
887 weighted gene level mixed effects differential expression models described Hoffman *et*
888 *al.* 2021 (dream) and enrichment using fgsea.

889 890 **Monocyte differentiation and perturbation pseudotime analysis**

891 To construct a combined monocyte differentiation and perturbation single cell map we
892 used the DDR tree algorithm with monocle²⁵⁷. The trajectory was constructed using the

893 genes that changed as a function of time (q value <0.15 using the differentialGeneTest
894 in monocle, with ribosomal genes and genes expressed in less than 15 cells removed).
895 The DDRtree algorithm⁵⁶ was implemented using the monocle function
896 reduceDimension with arguments *residualModelFormulaStr* = subjectID and
897 *max_components* = 2 and pseudotime calculated with function orderCells.
898 Independently of the genes used to construct the trajectory, we then tested the genes
899 from the mixed effects model of vaccination effects from monocytes (specific leading
900 edge genes from 'reactome interferon signaling', 'GO IL6 PRODUCTION', 'reactome IL4
901 and IL13 signaling', 'HALLMARK inflammatory response', 'KEGG JAK STAT signaling')
902 for branch dependent differential expression using the *BEAM* function from monocle.
903 Select genes were highlighted and categorized based on their expression dynamics
904 along real time and pseudotime.

905

906 **Cell frequency analysis**

907 Cell frequencies of activated monocytes gated as HLA-DR+ cells were computed as a
908 fraction of total CD45+CD14+ classical monocytes using flow cytometry data⁶. These
909 cell frequencies were compared across subjects (high vs. low responders) at baseline
910 using a two sided Wilcoxon rank test. The kinetic change of the cell frequency following
911 vaccination was modeled using a mixed effects model with a single random effect for
912 subject ID similar to the models described above. The kinetics over time were modeled
913 using an interaction for time and antibody response group (high vs. low AdjMFC). This
914 interaction model was compared to a timepoint only without the group interaction effect
915 with analysis of variance. The baseline versus day 1 effects for each antibody response
916 group was calculated using the emmeans package.

917

918 **Analysis of phospho-signaling responses after stimulation of high and low 919 responder baseline PBMCs using CyTOF**

920 Samples were thawed in a 37°C water bath and washed twice with warmed complete
921 media with Universal Nuclease (Pierce) added. Cells were then washed a final time and
922 resuspended in complete media. 1 million cells per condition were added to individual

923 wells and rested in a tissue culture incubator for 2 hours (37°C, 5% CO₂). Samples were
924 then stimulated with either PMA/Ionomycin (final concentration [10 ng/mL]/[1 µg/mL];
925 Sigma-Aldrich), LPS (final concentration [1 µg/mL]; Sigma-Aldrich), IFN-α (final
926 concentration [10,000U/ml], PBL Assay Science), or left unstimulated. After 15 minutes
927 at 37°C, samples were fixed with paraformaldehyde (2.2% PFA final concentration) for
928 10 minutes at 25°C. Samples were washed twice with Maxpar Barcode Perm Buffer (1X
929 concentration; Standard Biotech). Samples were then barcoded with Cell-ID 20-Plex Pd
930 Barcoding Kit (Standard Biotech) and incubated at 25°C for 30 minutes. Samples were
931 then washed twice with Maxpar Cell Staining Buffer (Standard Biotech) and combined
932 into corresponding barcoded batches of 5 samples (4 conditions per sample) and
933 washed a final time with Maxpar Cell Staining Buffer. Samples were then stained with a
934 titrated antibody-panel for extracellular markers (Supplementary Table) for 30 minutes
935 at 25°C. After staining, the cells were washed twice with Maxpar Cell Staining Buffer
936 and permeabilized in methanol (Fisher Scientific) overnight at -80°C. The next day,
937 samples were washed twice with Maxpar Cell Staining Buffer, and stained with a titrated
938 panel of antibodies for intracellular signaling markers (Supplementary Table) at 25°C for
939 30 minutes. Samples were then washed twice with Maxpar Cell Staining Buffer, and
940 labeled with Cell-ID Intercalator Ir ([1:2000] in Maxpar Fix-Perm Buffer; Standard
941 Biotech) overnight at 4°C. The following day, samples were washed twice with Maxpar
942 Cell Staining Buffer and resuspended in 500 µL freezing media (90% FBS (Atlanta
943 Biologicals) + 10% DMSO (Sigma-Aldrich)), and stored at -80°C until acquisition. The
944 day of acquisition, samples were thawed and washed twice with Maxpar Cell Staining
945 Buffer and then once with Cell Acquisition Solution (Standard Biotech) before being
946 resuspended in Cell Acquisition Solution supplemented with 10% EQ Four Element
947 Calibration Beads at a concentration of 6 x 10⁵ cells/mL (to approximate 300
948 events/sec). Samples were acquired on the Helios system (Standard Biotech) using a
949 WB Injector (Standard Biotech). After acquisition, samples were normalized and
950 debarcoded using the CyTOF Software's debarcoder and normalization tools (Standard
951 Biotech). The panel and protocol were adapted for use at CHI from the Stanford
952 HIMC¹¹⁰. The phosphor markers driving the stimulated phenotype and responding cells

953 were automatically defined using the HDStIM R package⁷⁰. The median phosphorylation
954 protein intensity for each individual sample and cell type and stimulation was calculated
955 and modeled with a mixed effects model adjusting for batch and using a random effect
956 for donor ID. The difference in fold change between unstimulated and stimulated cells
957 was calculated using a custom contrast with the emmeans package. CyTOF antibody
958 information is provided in **Supplemental Table 6**.

959 **Code availability**

960 Code to replicate all analysis in this paper and create all figures is available in the
961 following repository: <https://github.com/NIAID/fsc>.

962 **Data availability**

963 All data can be downloaded from the following repository: 10.5281/zenodo.7365959

964 **Acknowledgements**

965 The authors thank members of the Tsang lab for discussions related to this work. This
966 research was supported by the Intramural Research Program of the National Institute of
967 Allergy and Infectious Diseases (NIAID) and Intramural Programs of the NIH Institutes
968 supporting the Center for Human Immunology. Conceptual figures were created using
969 BioRender. The authors thank Eoin Mckinney, Gosia Trynka, Petter Brodin, Sarah
970 Teichman and Ken Smith for constructive comments on this work.

971 **References**

- 972
- 973 1. Brodin, P. & Davis, M. M. Human immune system variation. *Nature Reviews*
974 *Immunology* **17**, 21–29 (2017).
 - 975 2. Carr, E. J. *et al.* The cellular composition of the human immune system is shaped by
976 age and cohabitation. *Nature Immunology* **17**, 461–468 (2016).
 - 977 3. Liston, A., Humblet-Baron, S., Duffy, D. & Goris, A. Human immune diversity: from
978 evolution to modernity. *Nature Immunology* **22**, 1479–1489 (2021).
- 979

- 983 4. Tsang, J. S. Utilizing population variation, vaccination, and systems biology to study
984 human immunology. *Trends in Immunology* **36**, 479–493 (2015).
- 985 5. Pulendran, B., Li, S. & Nakaya, H. I. Systems Vaccinology. *Immunity* **33**, 516–529
986 (2010).
- 987 6. Tsang, J. S. *et al.* Global analyses of human immune variation reveal baseline
988 predictors of postvaccination responses. *Cell* **157**, 499–513 (2014).
- 989 7. Nakaya, H. I. *et al.* Systems Analysis of Immunity to Influenza Vaccination across
990 Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.
991 *Immunity* **43**, 1186–1198 (2015).
- 992 8. Querec, T. D. *et al.* Systems biology approach predicts immunogenicity of the yellow
993 fever vaccine in humans. *Nature Immunology* **10**, 116–125 (2009).
- 994 9. Sobolev, O. *et al.* Adjuvanted influenza-H1N1 vaccination reveals lymphoid
995 signatures of age-dependent early responses and of clinical adverse events.
996 *Nature Immunology* **17**, 740–740 (2016).
- 997 10. Furman, D. *et al.* Apoptosis and other immune biomarkers predict influenza vaccine
998 responsiveness. *Molecular Systems Biology* **9**, 1–14 (2013).
- 999 11. Bucasas, K. L. *et al.* Early patterns of gene expression correlate with the humoral
1000 immune response to influenza vaccination in humans. *Journal of Infectious*
1001 *Diseases* **203**, 921–929 (2011).
- 1002 12. Gaucher, D. *et al.* Yellow fever vaccine induces integrated multilineage and
1003 polyfunctional immune responses. *Journal of Experimental Medicine* **205**, 3119–
1004 3131 (2008).
- 1005 13. Obermoser, G. *et al.* Systems scale interactive exploration reveals quantitative and
1006 qualitative differences in response to influenza and pneumococcal vaccines.
1007 *Immunity* **38**, 831–844 (2013).
- 1008 14. Avey, S. *et al.* Seasonal Variability and Shared Molecular Signatures of Inactivated
1009 Influenza Vaccination in Young and Older Adults. *The Journal of Immunology* **204**,
1010 1661–1673 (2020).
- 1011 15. Franco, L. M. *et al.* Integrative genomic analysis of the human immune response to
1012 influenza vaccination. *eLife* **2013**, 1–18 (2013).

- 1013 16. Avey, S. *et al.* Multicohort analysis reveals baseline transcriptional predictors of
1014 influenza vaccination responses. *Science Immunology* **2**, eaal4656 (2017).
- 1015 17. Thakar, J. *et al.* Aging-dependent alterations in gene expression and a
1016 mitochondrial signature of responsiveness to human influenza vaccination. *Aging*
1017 **7**, 38–52 (2015).
- 1018 18. Furman, D. *et al.* Systems analysis of sex differences reveals an
1019 immunosuppressive role for testosterone in the response to influenza vaccination.
1020 *Proceedings of the National Academy of Sciences of the United States of America*
1021 **111**, 869–874 (2014).
- 1022 19. Fourati, S. *et al.* Pre-vaccination inflammation and B-cell signalling predict age-
1023 related hyporesponse to hepatitis B vaccination. *Nature Communications* **7**, 1–12
1024 (2016).
- 1025 20. Moncunill, G. *et al.* Transcriptional correlates of malaria in RTS,S/AS01-vaccinated
1026 African children: A matched case-control study. *eLife* **11**, 1–30 (2022).
- 1027 21. Tsang, J. S. *et al.* Improving Vaccine-Induced Immunity: Can Baseline Predict
1028 Outcome? *Trends in Immunology* **41**, 457–465 (2020).
- 1029 22. Kotliarov, Y. *et al.* Broad immune activation underlies shared set point signatures
1030 for vaccine responsiveness in healthy individuals and disease activity in patients
1031 with lupus. *Nature Medicine* **26**, 618–629 (2020).
- 1032 23. Fourati, S. *et al.* Pan-vaccine analysis reveals innate immune endotypes predictive
1033 of antibody responses to vaccination. *Nat Immunol* (2022) doi:10.1038/s41590-
1034 022-01329-5.
- 1035 24. Xhonneux, L. P. *et al.* Transcriptional networks in at-risk individuals identify
1036 signatures of type 1 diabetes progression. *Science Translational Medicine* **13**, 1–16
1037 (2021).
- 1038 25. Lozano, A. X. *et al.* T cell characteristics associated with toxicity to immune
1039 checkpoint blockade in patients with melanoma. *Nature Medicine* **28**, 353–362
1040 (2022).

- 1041 26. Zhao, C. *et al.* Contrasting autoimmune and treatment effects reveals baseline set
1042 points of immune toxicity following checkpoint inhibitor treatment. *bioRxiv* (2022)
1043 doi:10.1101/2022.06.05.494592.
- 1044 27. Germain, R. N. & Schwartzberg, P. L. The human condition: An immunological
1045 perspective. *Nature Immunology* **12**, 369–372 (2011).
- 1046 28. Germain, R. N. Will systems biology deliver its promise and contribute to the
1047 development of new or improved vaccines?: What really constitutes the study of
1048 “systems biology” and how might such an approach facilitate vaccine design. *Cold
1049 Spring Harbor Perspectives in Biology* **10**, (2018).
- 1050 29. Lu, Y. *et al.* Systematic Analysis of Cell-to-Cell Expression Variation of T
1051 Lymphocytes in a Human Cohort Identifies Aging and Genetic Associations.
1052 *Immunity* **45**, 1162–1175 (2016).
- 1053 30. Roederer, M. *et al.* The genetic architecture of the human immune system: A
1054 bioresource for autoimmunity and disease pathogenesis. *Cell* **161**, 387–403
1055 (2015).
- 1056 31. Lakshmikanth, T. *et al.* Human Immune System Variation during 1 Year. *Cell
1057 Reports* **32**, (2020).
- 1058 32. Stoeckius, M. *et al.* Simultaneous epitope and transcriptome measurement in
1059 single cells. *Nature Methods* **14**, 865–868 (2017).
- 1060 33. Garçon, N., Vaughn, D. W. & Didierlaurent, A. M. Development and evaluation of
1061 AS03, an Adjuvant System containing α -tocopherol and squalene in an oil-in-water
1062 emulsion. *Expert Review of Vaccines* **11**, 349–366 (2012).
- 1063 34. Khurana, S. *et al.* AS03-adjuvanted H5N1 vaccine promotes antibody diversity and
1064 affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-
1065 subtype neutralization. *npj Vaccines* **3**, 40 (2018).
- 1066 35. Howard, L. M. *et al.* AS03-adjuvanted H5N1 avian influenza vaccine modulates
1067 early innate immune signatures in human peripheral blood mononuclear cells.
1068 *Journal of Infectious Diseases* **219**, 1786–1798 (2019).

- 1069 36. de Mot, L. *et al.* Transcriptional profiles of adjuvanted hepatitis B vaccines display
1070 variable interindividual homogeneity but a shared core signature. *Science*
1071 *Translational Medicine* **12**, 1–14 (2020).
- 1072 37. Mulè, M. P., Martins, A. J. & Tsang, J. S. Normalizing and denoising protein
1073 expression data from droplet-based single cell profiling. *Nature Communications*
1074 **13**, 2020.02.24.963603 (2022).
- 1075 38. Ellebedy, A. H. *et al.* Defining antigen-specific plasmablast and memory B cell
1076 subsets in human blood after viral infection or vaccination. *Nature Immunology* **17**,
1077 1226–1234 (2016).
- 1078 39. The GTEx Consortium *et al.* The Genotype-Tissue Expression (GTEx) pilot
1079 analysis: Multitissue gene regulation in humans. *Science* **348**, 648–660 (2015).
- 1080 40. Uhlen, M. *et al.* A genome-wide transcriptomic analysis of protein-coding genes in
1081 human blood cells. *Science* **366**, eaax9198 (2019).
- 1082 41. Chang, W. C. *et al.* Genetic variants of PPAR-gamma coactivator 1B augment
1083 NLRP3-mediated inflammation in gouty arthritis. *Rheumatology (United Kingdom)*
1084 **56**, 457–466 (2017).
- 1085 42. Segovia, M. *et al.* Targeting TMEM176B Enhances Antitumor Immunity and
1086 Augments the Efficacy of Immune Checkpoint Blockers by Unleashing
1087 Inflammasome Activation. *Cancer Cell* **35**, 767-781.e6 (2019).
- 1088 43. Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing,
1089 cardiovascular disease, and frailty. *Nature Reviews Cardiology* **15**, 505–522
1090 (2018).
- 1091 44. Hagan, T. *et al.* Transcriptional atlas of the human immune response to 13
1092 vaccines reveals a common predictor of vaccine-induced antibody responses. *Nat*
1093 *Immunol* (2022) doi:10.1038/s41590-022-01328-6.
- 1094 45. Nakaya, H. I. *et al.* Systems biology of vaccination for seasonal influenza in
1095 humans. *Nature Immunology* **12**, 786–795 (2011).
- 1096 46. Nordmann, A., Wixler, L., Boergeling, Y., Wixler, V. & Ludwig, S. A new splice
1097 variant of the human guanylate-binding protein 3 mediates anti-influenza activity

- 1098 through inhibition of viral transcription and replication. *FASEB j.* **26**, 1290–1300
1099 (2012).
- 1100 47. Hsiang, T.-Y., Zhao, C. & Krug, R. M. Interferon-Induced ISG15 Conjugation
1101 Inhibits Influenza A Virus Gene Expression and Replication in Human Cells. *J Virol*
1102 **83**, 5971–5977 (2009).
- 1103 48. Li, Y. *et al.* Activation of RNase L is dependent on OAS3 expression during
1104 infection with diverse human viruses. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 2241–2246
1105 (2016).
- 1106 49. Qu, H. *et al.* Influenza A Virus-induced expression of ISG20 inhibits viral replication
1107 by interacting with nucleoprotein. *Virus Genes* **52**, 759–767 (2016).
- 1108 50. Fantuzzi, L. *et al.* Loss of CCR2 Expression and Functional Response to Monocyte
1109 Chemotactic Protein (MCP-1) During the Differentiation of Human Monocytes: Role
1110 of Secreted MCP-1 in the Regulation of the Chemotactic Response. *Blood* **94**,
1111 875–883 (1999).
- 1112 51. Kuss-Duerkop, S. K. *et al.* Influenza virus differentially activates mTORC1 and
1113 mTORC2 signaling to maximize late stage replication. *PLoS Pathog* **13**, e1006635
1114 (2017).
- 1115 52. Weichhart, T. *et al.* The TSC-mTOR Signaling Pathway Regulates the Innate
1116 Inflammatory Response. *Immunity* **29**, 565–577 (2008).
- 1117 53. Li, S. *et al.* Metabolic Phenotypes of Response to Vaccination in Humans. *Cell* **169**,
1118 862-877.e17 (2017).
- 1119 54. Cheng, S.-C. *et al.* mTOR- and HIF-1 α -mediated aerobic glycolysis as metabolic
1120 basis for trained immunity. *Science* **345**, 1250684 (2014).
- 1121 55. Marçais, A. *et al.* The metabolic checkpoint kinase mTOR is essential for IL-15
1122 signaling during the development and activation of NK cells. *Nat Immunol* **15**, 749–
1123 757 (2014).
- 1124 56. Mao, Q., Wang, L., Tsang, I. W. & Sun, Y. Principal Graph and Structure Learning
1125 Based on Reversed Graph Embedding. *IEEE Transactions on Pattern Analysis and*
1126 *Machine Intelligence* **39**, 2227–2241 (2017).

- 1127 57. Qiu, X. *et al.* Reversed graph embedding resolves complex single-cell trajectories.
1128 *Nature Methods* **14**, 979–982 (2017).
- 1129 58. Howard, L. M. *et al.* Cell-based systems biology analysis of human AS03-
1130 adjuvanted H5N1 avian influenza vaccine responses: A phase i randomized
1131 controlled trial. *PLoS ONE* **12**, (2017).
- 1132 59. Bloes, D. A., Kretschmer, D. & Peschel, A. Enemy attraction: Bacterial agonists for
1133 leukocyte chemotaxis receptors. *Nature Reviews Microbiology* **13**, 95–104 (2015).
- 1134 60. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a
1135 cytosolic DNA sensor that activates the type I interferon pathway. *Science* **339**,
1136 786–91 (2013).
- 1137 61. Sallusto, F. *et al.* Rapid and coordinated switch in chemokine receptor expression
1138 during dendritic cell maturation. *European Journal of Immunology* **28**, 2760–2769
1139 (1998).
- 1140 62. Chhatbar, C. & Prinz, M. The roles of microglia in viral encephalitis: from sensome
1141 to therapeutic targeting. *Cellular and Molecular Immunology* **18**, 250–258 (2021).
- 1142 63. Hoshino, K. *et al.* Toll-Like Receptor 4 (TLR4)-Deficient Mice Are Hyporesponsive
1143 to Lipopolysaccharide: Evidence for TLR4 as the Lps Gene Product. *Journal of*
1144 *immunology* **162**, 3749–3752 (1999).
- 1145 64. Wensveen, F. M. *et al.* Apoptosis threshold set by noxa and Mcl-1 after T cell
1146 activation regulates competitive selection of high-affinity clones. *Immunity* **32**, 754–
1147 765 (2010).
- 1148 65. Wensveen, F. M. *et al.* BH3-only protein Noxa regulates apoptosis in activated B
1149 cells and controls high-affinity antibody formation. *Blood* **119**, 1440–1449 (2012).
- 1150 66. Gricks, C. S. *et al.* Differential regulation of gene expression following CD40
1151 activation of leukemic compared to healthy B cells. *Blood* **104**, 4002–4009 (2004).
- 1152 67. Shimabukuro-Vornhagen, A. *et al.* Inhibition of Protein Geranylgeranylation
1153 Specifically Interferes with CD40-Dependent B Cell Activation, Resulting in a
1154 Reduced Capacity To Induce T Cell Immunity. *The Journal of Immunology* **193**,
1155 5294–5305 (2014).

- 1156 68. Arunachalam, P. S. *et al.* Systems vaccinology of the BNT162b2 mRNA vaccine in
1157 humans. *Nature* **596**, 410–416 (2021).
- 1158 69. Hogan, M. J. & Pardi, N. mRNA Vaccines in the COVID-19 Pandemic and Beyond.
1159 *Annual Review of Medicine* **73**, 17–39 (2022).
- 1160 70. Farmer, R. *et al.* Multiparameter stimulation mapping of signaling states in single
1161 pediatric immune cells reveals heightened tonic activation during puberty. *Biorxiv*
1162 (2022) doi:10.1101/2022.11.14.516371.
- 1163 71. Doyle, S. E. *et al.* IRF3 Mediates a TLR3/TLR4-Specific Antiviral Gene Program.
1164 *Immunity* **17**, 251–263 (2002).
- 1165 72. Kawai, T. Toll-like receptor signaling pathways. *Frontiers in Immunology*.
- 1166 73. Mikkelsen, S. S. *et al.* RIG-I-mediated Activation of p38 MAPK Is Essential for Viral
1167 Induction of Interferon and Activation of Dendritic Cells. *Journal of Biological*
1168 *Chemistry* **284**, 10774–10782 (2009).
- 1169 74. Kulkarni, R. R. *et al.* Activation of the RIG-I Pathway during Influenza Vaccination
1170 Enhances the Germinal Center Reaction, Promotes T Follicular Helper Cell
1171 Induction, and Provides a Dose-Sparing Effect and Protective Immunity. *J Virol* **88**,
1172 13990–14001 (2014).
- 1173 75. Chari, T., Banerjee, J. & Pachter, L. The Specious Art of Single-Cell Genomics.
1174 *bioRxiv* (2021) doi:10.1101/2021.08.25.457696.
- 1175 76. Zimmerman, K. D., Espeland, M. A. & Langefeld, C. D. A practical solution to
1176 pseudoreplication bias in single-cell studies. *Nat Commun* **12**, 738 (2021).
- 1177 77. Aaby, P., Netea, M. G. & Benn, C. S. Beneficial non-specific effects of live vaccines
1178 against COVID-19 and other unrelated infections. *The Lancet Infectious Diseases*
1179 **23**, e34–e42 (2023).
- 1180 78. Old, L. J., Clarke, D. A. & Benacerraf, B. Effect of Bacillus Calmette-Guérin
1181 Infection on Transplanted Tumours in the Mouse. *Nature* **184**, 291–292 (1959).
- 1182 79. Giamarellos-Bourboulis, E. J. *et al.* Activate: Randomized Clinical Trial of BCG
1183 Vaccination against Infection in the Elderly. *Cell* **183**, 315-323.e9 (2020).
- 1184 80. Netea, M. G. *et al.* Defining trained immunity and its role in health and disease.
1185 *Nature Reviews Immunology* **20**, 375–388 (2020).

- 1186 81. Boraschi, D. & Italiani, P. Innate Immune Memory: Time for Adopting a Correct
1187 Terminology. *Front. Immunol.* **9**, 799 (2018).
- 1188 82. Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of
1189 inflammation by TLR-induced chromatin modifications. *Nature* **447**, 972–978
1190 (2007).
- 1191 83. Keenan, A. B. *et al.* ChEA3: transcription factor enrichment analysis by orthogonal
1192 omics integration. *Nucleic Acids Research* **47**, W212–W224 (2019).
- 1193 84. de Laval, B. *et al.* C/EBP β -Dependent Epigenetic Memory Induces Trained
1194 Immunity in Hematopoietic Stem Cells. *Cell Stem Cell* **26**, 657-674.e8 (2020).
- 1195 85. Brodin, P. *et al.* Variation in the Human Immune System Is Largely Driven by Non-
1196 Heritable Influences. *Cell* **160**, 37–47 (2015).
- 1197 86. Furman, D. *et al.* Cytomegalovirus infection enhances the immune response to
1198 influenza. *Science Translational Medicine* **7**, 281ra43-281ra43 (2015).
- 1199 87. Weinberger, B. *et al.* Impaired Immune Response to Primary but Not to Booster
1200 Vaccination Against Hepatitis B in Older Adults. *Front. Immunol.* **9**, 1035 (2018).
- 1201 88. Austin, J. W. *et al.* Overexpression of T-bet in HIV infection is associated with
1202 accumulation of B cells outside germinal centers and poor affinity maturation. *Sci.*
1203 *Transl. Med.* **11**, eaax0904 (2019).
- 1204 89. Havenar-Daughton, C. *et al.* Normal human lymph node T follicular helper cells and
1205 germinal center B cells accessed via fine needle aspirations. *Journal of*
1206 *Immunological Methods* **479**, 112746 (2020).
- 1207 90. Patricia D'Souza, M. *et al.* Innovative approaches to track lymph node germinal
1208 center responses to evaluate development of broadly neutralizing antibodies in
1209 human HIV vaccine trials. *Vaccine* **36**, 5671–5677 (2018).
- 1210 91. Turner, J. S. *et al.* Human germinal centres engage memory and naive B cells after
1211 influenza vaccination. *Nature* **586**, 127–132 (2020).
- 1212 92. Lareau, C. A. *et al.* Massively parallel single-cell mitochondrial DNA genotyping
1213 and chromatin profiling. *Nature Biotechnology* **39**, 451–461 (2021).
- 1214 93. Sparks, R. *et al.* Influenza vaccination reveals sex dimorphic imprints of prior mild
1215 COVID-19. *Nature* (2023) doi:10.1038/s41586-022-05670-5.

- 1216 94. Wimmers, F. *et al.* The single-cell epigenomic and transcriptional landscape of
1217 immunity to influenza vaccination. *Cell* **184**, 3915-3935.e21 (2021).
- 1218 95. Stoeckius, M. *et al.* Cell Hashing with barcoded antibodies enables multiplexing
1219 and doublet detection for single cell genomics. *Genome Biology* **19**, 237693
1220 (2018).
- 1221 96. McGinnis, C. S. *et al.* MULTI-seq: sample multiplexing for single-cell RNA
1222 sequencing using lipid-tagged indices. *Nature Methods* **16**, 619–626 (2019).
- 1223 97. Kang, H. M. *et al.* Multiplexed droplet single-cell RNA-sequencing using natural
1224 genetic variation. *Nature Biotechnology* **36**, 89–94 (2018).
- 1225 98. McCarthy, D. J., Campbell, K. R., Lun, A. T. L. & Wills, Q. F. Scater: Pre-
1226 processing, quality control, normalization and visualization of single-cell RNA-seq
1227 data in R. *Bioinformatics* **33**, 1179–1186 (2017).
- 1228 99. Lun, A. T. L., Bach, K. & Marioni, J. C. Pooling across cells to normalize single-cell
1229 RNA sequencing data with many zero counts. *Genome Biology* **17**, 1–14 (2016).
- 1230 100. Waltman, L. & Van Eck, N. J. A smart local moving algorithm for large-scale
1231 modularity-based community detection. *European Physical Journal B* **86**, (2013).
- 1232 101. Hoffman, G. E. & Schadt, E. E. variancePartition: Interpreting drivers of variation in
1233 complex gene expression studies. *BMC Bioinformatics* **17**, 17–22 (2016).
- 1234 102. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. Voom: Precision weights unlock
1235 linear model analysis tools for RNA-seq read counts. *Genome Biology* **15**, R29
1236 (2014).
- 1237 103. Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects
1238 models using lme4. *Journal of Statistical Software* **67**, (2015).
- 1239 104. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package
1240 for differential expression analysis of digital gene expression data. *Bioinformatics*
1241 **26**, 139–140 (2009).
- 1242 105. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis.
1243 Preprint of BioRxiv. *bioRxiv* 1–29 (2019) doi:10.1101/060012.
- 1244 106. Li, S. *et al.* Molecular signatures of antibody responses derived from a systems
1245 biology study of five human vaccines. *Nature Immunology* **15**, 195–204 (2014).

- 1246 107. Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment
1247 analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
- 1248 108. Ritchie, M. E. *et al.* Limma powers differential expression analyses for RNA-
1249 sequencing and microarray studies. *Nucleic Acids Research* **43**, e47 (2015).
- 1250 109. Lenth, Russel V. emmeans: Estimated Marginal Means, aka Least-Squares Means.
- 1251 110. Fernandez, R. & Maecker, H. Cytokine-stimulated Phosphoflow of PBMC Using
1252 CyTOF Mass Cytometry. *BIO-PROTOCOL* **5**, (2015).

1253

1254




Figure S1. (related to Figure 1) quality control of CITE-seq transcriptome and surface protein phenotypes and clustering

a. Manually gated cell populations based on dsb normalized CITE-seq surface protein expression, orange box: plasmablast (CD19+CD71+IgD-CD20-CD38++) and blue box: activated B cell (CD19+CD71+IgD-CD20+CD38+/-). **b.** Transcriptome analysis of gene module scores specific to each gated populations (as in Ellebedy et. al. 2016) p-values shown reflect an unpaired two-sided Wilcoxon test between populations. **c.** Density distribution of dsb normalized protein expression binned by protein based cluster for select populations. **d.** Histograms of dsb normalized protein distribution within each protein-based cluster – rows and columns are hierarchically clustered based on the average expression per cluster. A select subset of proteins are shown and are colored by the main cell populations that they are most informative for discriminating. Red = T cell proteins, light blue = B cell proteins, green = monocyte proteins, dark blue = NK cell proteins, orange = pDC proteins, pink = pDC/HSC markers, black = cell state markers. **e.** The percentage of total cells for each PBMC sample in each major lineage black = B cell, orange = CD4 T cells, blue = CD8 T cells, red = myeloid (all monocytes, HSC, mDC and pDC), green = NK cells, light grey = unconventional T cells (MAIT-like and CD103 + T cells). **f.** The log number of cells per sample by protein based cluster shows that rare individual specific proteins are detected at both timepoints within a given individual.




Figure S2 (related to Figure 2). Deconvolution of day 7 antibody titer associated transcriptome signatures and additional shared and cell type specific day 1 cell perturbation phenotypes.

a. Perturbation phenotypes of naïve B cells day 7 post vaccination. Gene set enrichment as in Fig. 2 based on model adjusted post vaccination effect size, adjusted $-\log_{10}$ p values shown as circle size; pathways with unadjusted p values < 0.01 and NES > 0.1 were included. **b.** As in a, for memory CD4 T cells. **c.** Protein based cell type specificity of day-7 bulk transcriptomic based gene expression signatures predictive of antibody response from previous systems biology studies of influenza vaccination (Supplementary table 1). Single cell level module score distribution shown for day 7 cells for each cell type. **d.** Correlation between genes in M156 detected in CITE-seq (sample level pseudobulk) vs microarray data (Pearson correlation). **e.** Composition of raw counts of the TNFRSF17 gene, a driver of M156 on day 7 across protein-based cell types shows the CD38⁺⁺ B cells (plasmablasts) are the primary source of the signal. **f.** Left: Heatmap of estimated log fold change 24h post vaccination vs baseline of a core interferon signature shared across subsets – genes selected were increased in at least 5 subsets with $\log_{2}FC > 0.1$ and p value < 0.05 . Right: the average expression of the core shared interferon signature genes across subsets over time. **g.** Log fold changes as in f, here highlighting genes more specifically induced within a single cell type post vaccination.





Figure S3 (related to Figure 3) external cohort validation of AS03 perturbation phenotypes and additional analysis of AS03 B cell phenotypes

a. Schematic illustrating the contrast applied to each gene comparing unadjuvanted subjects to subjects receiving the AS03 adjuvanted vaccine. The gene set enrichment effect sizes (normalized enrichment score–NES) reflect the genes ranked by the difference in the day 1 fold changes. **b.** Gene set enrichment of the contrast effect shown in **a** from the mixed effect model for Naïve B cells. **c.** Naïve B cells single cell mixed effects model of a combined apoptosis signature comparing the day 1 fold change AS03 vs unadjuvanted subjects as a function of time post vaccination. The effect size for the time effect for each cohort was opposite, (bottom contrast on bottom margin of plot). The right margin shows the estimated marginal means of the mixed model over levels of the combined vaccine formulation cohort + timepoint variable as calculated by the emmeans package. **d.** External cohort validation of Naïve B cell CITE-seq derived perturbation phenotypes tested in validation cohort (see Fig 3a) of total sorted B cells (Naïve B cell AS03-specific leading edge genes from CITE-seq analysis as shown in Supplementary Fig 3b tested in all CD19+ cells in the validation cohort). The additional survival signals highlighted in light blue hypothesized to be enriched in naïve B cells after AS03 adjuvanted vaccination based on the M160 genes and top AS03 specific downregulated genes (Fig 3e) and their expression in the CITE-seq cohort include the combined “apoptosis signature” and CD40 activation (CD40 ACT) signature (see methods).

a



b




Figure S4. (related to Figure 4) immune setpoint network of high responders

a. Correlated multicellular baseline high responder cell phenotypes as a network.

The matrix shows the Spearman correlation of expression of each gene module leading edge genes defined in high vs low responders across donors. Correlations within a given cell type are adjusted for gene content (see methods) as exhibited by the diagonal of the matrix (correlations between the same signals) showing a correlation of 0 instead of 1. **b.** The hub score of nodes in the high responder setpoint network after removing edges with correlation adjusted $p < 0.05$ and those with connection strength (Spearman's Rho for intercellular connections or shared latent information for intracellular connections) below the median in the network. Nodes highlighted with text include all CD14 and CD16 monocyte nodes including those show in in Figs 4b-c. Points are colored by cell type; the annotation of modules may be the same for a given row (e.g. reactome interferon in CD14 and CD16 monocytes) but the same module is captured by different genes driving the high responder effect in each cell type (e.g. they reflect cell type specific cell phenotypes).